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You never change things by fighting the existing reality.          
To change something, build a new model that makes the 
existing model obsolete. 
Buckminster Fuller (1895 - 1983) 
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1 Introduction 
1.1 Background 
Background 
Approximately 400 patients with oncological or haematological neoplasias admitted 
for chemotherapy at the University Medical Centre Freiburg were recruited in differ-
ent but overlapping prospective observation surveys. The surveys all incorporated a 
detailed assessment of nutritional status including anthropometric measurements, 
diet history, life style, medical records, serum 25-hydroxyvitamin D3, and antioxida-
tive status in serum and buccal mucosa cells. The three consecutive assessment 
events took place at the start of each new chemotherapy cycle, or at main diagnostic 
time points in patients undergoing allogeneic haematopoietic cell transplantation 
(alloHCT). 
Complete data collection resulted in part from supervising five diploma theses and 
one medical PhD. Some of the data were utilised to develop and validate oncoMAT® 
software, which is programmed for the evaluation and prediction of cancer patients' 
nutritional status. 
On behalf of the present cumulative doctoral thesis, a homogeneous collective of 105 
patients admitted for high-dose chemotherapy followed by alloHCT was selected, re-
sulting in four original research articles. These publications focused mainly on the 
potential impacts of nutritional and antioxidative status on clinically-relevant, post-
transplant outcomes. 
In addition, an experimental and randomised controlled clinical trial with 27 healthy 
young volunteers was carried out, leading to a further original research article. That 
trial investigated a new approach with which to improve a specific aspect of nutri-
tional status, namely vitamin D, which is known to be insufficient in the general 
population, most particularly in patients undergoing alloHCT.  
1.2 Topic of this thesis 
Topic of present thesis 
Allogeneic haematopoietic cell transplantation (alloHCT) is a risky but potentially 
curative treatment in patients with diseases of the blood and bone marrow or certain 
types of cancer [1]. However, this procedure can cause many complications ranging 
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from mucositis, infections and graft-versus-host disease (GVHD) to treatment- or 
progression-related mortality [2-4]. 
Nutritional status in alloHCT  
AlloHCT-associated complications and their medical treatments often cause tremen-
dous changes in body composition, especially through disturbed muscle metabolism 
[5,6]. There is a paucity of studies assessing nutritional status before alloHCT, most 
of which only recorded body mass index (BMI) as a potential risk factor for overall 
survival [7-10]. Except for one report by Kyle et al. [11] on the  development of lean 
body mass, there was until now no longitudinal data on nutritional status and body 
composition in the early post-transplant period. 
The main objective of this prospective study (2.2 on page 18) was to assess the nu-
tritional status in patients before alloHCT and its course in the early post-transplant 
period until day +100 via weight changes prior to alloHCT, body mass index (BMI) 
normalized for gender and age [12], the Subjective Global Assessment (SGA) ques-
tionnaire [13], and phase angle normalized for gender, age and BMI [14]. This is the 
first and in-depth evaluation of the risk factors associated with nutritional status and 
body composition in patients undergoing alloHCT. 
Nutritional status - impact on outcome  
There are great research efforts now being made to identify risk factors for outcome 
in patients under consideration for alloHCT so as to improve the selection for this 
intensive treatment [15,16] and, in the case of potentially modifiable factors, to de-
velop new strategies for improving individual outcomes. Beyond the well-known risk 
factors such as recipient age, remission status at alloHCT, donor status, conditioning 
regimen, HLA has been evaluated and identified as being of prognostic value in these 
patients [7-10].  
We have available a large number of parameters assessing nutritional status and 
validated as risk factors in cancer patients for a multitude of clinical and economic 
outcomes ranging from quality of life, length of hospital stay and infections to overall 
survival [17-20]. However, the relevance of common nutritional parameters other 
than BMI as risk factors for outcome in patients undergoing alloHCT remains un-
known. 
The aim of this prospective analysis (2.1 on page 5) was to investigate the validity of 
the major nutritional parameters: BMI, SGA questionnaire and phase angle as inde-
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pendent risk factors for outcome until two years after alloHCT, using a multivariate 
model analysis including a variety of accepted risk factors. 
Antioxidative status - impact on the incidence oral mucositis 
Oral mucositis (OM), a leading adverse effect of radio- and chemotherapy condition-
ing preceding alloHCT, remains a significant complication during the early post-
transplant period [21]. Consequences of OM range from soreness and painful ulcera-
tions to malnutrition and life-threatening infections, and it is associated with signifi-
cantly worse clinical and economic outcomes [22,23]. Furthermore, there is no pre-
ventive or treatment regime for OM, and little is known of risk factors for its 
occurrence [24,25].  
A major stimulus in the pathogenesis of OM is the induction of reactive oxygen spe-
cies [24] which leads to tissue damage triggered by the tissue damage caused  by 
chemotherapy and/or radiation [26,27]. In contrast, the endogenous antioxidative 
system and exogenous antioxidants (AOX) such as α-tocopherol (vitamin E), ascorbic 
acid (vitamin C), and ß-carotene scavenge free radicals and may thus reduce the 
incidence and severity of OM [28,29]. AOX are usually measured in plasma, but this 
does not necessarily provide evidence of the supply in the target tissue. Therefore, 
the determination of AOX status at the main site of action, namely the buccal muco-
sal cells, could be more reliable [28,30]. 
The study under 2.3 on page 29 is the first to have investigated the association 
between the incidence and severity of OM and AOX status in buccal mucosa cells and 
plasma before conditioning chemotherapy followed by alloHCT. 
Vitamin D status and its influencing factors 
In addition to the potential impact of nutritional and antioxidative status on clinically 
relevant outcomes in patients undergoing alloHCT, recent studies suggest that 
hypovitaminosis D (<30 ng/ml) at diagnosis may be associated with poorer progno-
sis in a wide range of solid malignancies [31-34]. Moreover, a recent study by 
Shanafelt el al. [35] provided the first actual evidence that hypovitaminosis D could 
be associated with worse outcome in patients with a haematological malignancy. A 
further health implication of vitamin D is the potential reduction in adverse effects of 
graft-versus-host disease (GVHD) based on vitamin D’s immunomodulatory proper-
ties [36]. 
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Hypovitaminosis D is highly prevalent in adult [37,38] and paediatric patients [39] 
undergoing alloHCT, but potential influencing factors of serum vitamin D status    
(25-hydroxyvitamin D) have only been reported in paediatric patients [39].  
To deepen understanding and develop future preventive and interventional ap-
proaches, the main objective of the research article 2.4 on page 39 was to determine 
those factors exerting significant influence on vitamin D status before conditioning 
chemotherapy followed by alloHCT in adult patients. A further objective was to de-
scribe the impact of influencing factors on the course of serum 25(OH)D3 during the 
early post-transplant period. 
New approach for improving vitamin D supply 
As already mentioned, hypovitaminosis D is highly prevalent in patients undergoing 
alloHCT [39,37,38] and a public health issue prevalent worldwide [40-43], particu-
larly in regions with a large seasonal shift in solar altitude, as the major source of 
vitamin D for humans is sunlight-induced cutaneous synthesis [44,45]. Moreover, few 
foods contain vitamin D in noteworthy concentrations; those that do are fish-liver 
oils, fatty fish, and egg yolk. Mushrooms contain very little if any vitamin D2, but 
they are abundant in ergosterol [46,47], which can be converted into vitamin D2 via 
ultraviolet (UV) irradiation [48,49].  
The randomised controlled trial under 2.5 on page 52 the first report on the bioavail-
ability of vitamin D2 from vitamin D2-enhanced mushrooms by UV-B in humans. 
Hence the primary objective of this randomised controlled trial was to demonstrate 
the potential of improving the 25-hydroxyvitamin D status with this natural food 
source via a higher serum 25OHD concentration in young and healthy adults with low 
25-hydroxyvitamin D status. A secondary objective was to compare the bioavailabil-
ity of vitamin D2 from UV-B treated mushrooms with a vitamin D2 supplement. 
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2 Original research articles 
2.1 Body mass index and bioelectrical impedance phase angle as 
potentially modifiable nutritional markers are independent 
risk factors for outcome in allogeneic haematopoietic cell 
transplantation 
Risk factors for outcome 
2.1.1 Introduction 
Allogeneic haematopoietic cell transplantation (alloHCT) is a risky but potentially 
curative treatment that can cause many complications, ranging from mucositis, in-
fections, and graft-versus-host disease (GVHD), to treatment- or progression-related 
mortality [2-4]. There are great research efforts being made to identify risk factors 
for outcome in patients being considered for alloHCT so as to improve the selection 
for this intensive treatment [15,16] and as regards potentially modifiable factors, to 
develop new strategies for improving individual outcomes. Besides the widely-
accepted risk factors such as recipient age, remission at HCT, donor status, condi-
tioning regimen, and HLA compatibility, only body mass index (BMI) - weight normal-
ized for height and a broad marker of nutritional status - has been evaluated so far 
and identified as having prognostic value in these patients. Under- and overweight 
patients are at increased risk for complications, non-relapse mortality and overall 
survival after alloHCT [7-10].  
A large number of parameters assessing nutritional status are currently available and 
validated as risk factors for cancer patients for a multitude of clinical and economic 
outcomes, ranging from quality of life, length of hospital stay, infections, to overall 
survival [17-20]. One example is the phase angle, which is measured by bioelectrical 
impedance analysis and reflects cell membrane function [50] and indirectly the 
body’s muscle mass [51]. It is an established parameter for the diagnosis of malnu-
trition, and a useful prognostic outcome marker in many clinical conditions [52] in-
cluding several types of cancer [53,54,18,55]. Another well-established prognostic 
parameter is the Subjective Global Assessment (SGA) questionnaire according to 
Detsky et al. [13], which has been proven to provide the best combination of sensi-
tivity and specificity in identifying complications related to malnutrition [56] and sur-
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vival [57], making this questionnaire a validated tool to evaluate nutritional status in 
cancer patients [20]. However, the relevance of common nutritional parameters 
apart from BMI as risk factors for outcome in patients undergoing alloHCT is still un-
known.  
This is the first prospective study to investigate the validity of several nutritional pa-
rameters [weight change before admission; adjusted BMI, normalised for gender and 
age; SGA questionnaire; and standardised phase angle, normalised for gender, age 
and BMI] as independent risk factors for outcome until two years after alloHCT, using 
a multivariate model analysis including a variety of widely-accepted risk factors. 
2.1.2 Subjects and methods 
Study population  
Adult patients with haematological malignancies admitted for alloHCT to our institu-
tion at University Medical Centre Freiburg between 2008 and 2010 were eligible to 
enter this prospective survey. The study protocol was approved by our local Ethics 
Committee, and all patients provided informed consent.  
Study design and data collection 
Nutritional status at admission was assessed in 105 patients by measuring weight, 
performing bioelectrical impedance analysis, and assessing nutritional status classifi-
cation according to the Subjective Global Assessment (SGA) questionnaire. In addi-
tion, weight changes over the previous six months and body height were recorded. 
All other medical and outcome data were collected from hospital records.  
Adjusted body mass index (BMI). Considering the BMI's age and gender depend-
encies, we used current and representative German BMI percentiles to categorise 
each value as low (<10th percentile), normal (10-90th percentile) or high (>90th 
percentile) according to age- and gender-specific BMI percentiles [12].  
Subjective Global Assessment (SGA). The SGA questionnaire according to Detsky 
et al. [13] is a simple, validated bedside tool in cancer patients with which to subjec-
tively evaluate nutritional status. It focuses on weight-loss history, relevant symp-
toms impairing nutrition intake, and a basic physical examination, and requires no 
equipment. Patients were classified as well nourished (SGA-A), moderately malnour-
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ished (SGA-B), and severely malnourished (SGA-C). The SGA questionnaire score 
has been shown to be associated with quality of life [17], length of hospital stay 
[19], and survival in cancer patients [57].  
Standardised phase angle. Bioelectrical impedance analysis is a validated, non-
invasive and portable method to estimate body composition with specific algorithms 
based on the electrical properties of body tissues [58]. Bioelectrical impedance 
analysis can be useful in assessing and monitoring nutritional status [50,59]. Phase 
angle, one of the raw data obtained from bioelectrical impedance analysis measure-
ments and thus independent from the equipment and internal algorithms used, has 
proved to be a good prognostic, nutritional, and membrane cell function marker in 
various diseases [53,60,61,55]. Sex-, age-, and BMI-specific reference values of 
phase angle from a large healthy German population [14] were used to calculated 
the standardised phase angle according to the formula standardised phase angle = 
(phase angle - phase angleref)/SDref, where phase angleref and SDref are the age-, 
sex- and BMI-specific mean and standard deviations in a healthy population, respec-
tively. Positive values are expected for healthy individuals [62]. The transformation 
of phase angle values into standardised values (Z-score) allows us to quantify indi-
vidual deviations from sex-, age-, and BMI-specific population averages and to com-
pare subjects in heterogeneous groups. In addition, Norman et al. [51] demon-
strated that this standardisation clearly enhances the predictive power of phase 
angle. Our analysis was performed using a multifrequency device (Body Scout in-
strument, Fresenius Medical Care, Germany) under standardised conditions [63]. The 
cut-off value was defined as the lower quartile (25th percentile = -2.26) of the stan-
dardised phase angle in our study sample [extremely low (≤-2.26) vs. low/normal 
(>2.26) values]. 
Statistical analysis 
We used IBM SPSS 19 (IBM, NY, USA) and SAS 9.2 (SAS Institute Inc., Cary, NC, 
USA) software for statistical analysis. Mean and standard deviations (SD) were used 
in case of approximately symmetric distributions, and when useful min-max as well. 
Overall survival (OS) was calculated as time from transplantation until death from 
any cause, and progression-free survival (PFS) was calculated as time from trans-
plantation to the first observation of disease progression or death from any cause. If 
the event of interest was not observed, observation times were censored at the time 
of last contact with the patient. We focused on the analysis of OS and PFS within the 
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2 years after transplantation, therefore observation times were censored after 2 
years at the latest. Patients who died without evidence of relapse or progression 
were considered as cases of non-relapse mortality (NRM). NRM and relapse mortality 
(RM) were considered as competing risks, and cumulative incidence rates were cal-
culated to estimate the respective rates. Prognostic factors were analysed by means 
of Cox proportional hazards regression models. We conducted univariate analyses 
first. A multivariate model was then applied including those factors with univariate P 
<0.2 as an initial variable set and performing a variable selection procedure (back-
ward elimination, retaining factors if P<0.1). For RM and NRM, Cox models were ap-
plied with censoring for the competing event, thus analysing the impact of prognostic 
factors on event-specific hazard rates. In addition to the four nutritional parameters, 
we included as potential risk and confounding factors the following variables in the 
Cox regression: recipient age and gender, donor age, gender and status, remission 
status at HCT, diagnosis, HLA compatibility (C; A, B, DRB), conditioning type, HCT-
Comorbidity Index score, Karnofsky Performance Status (KPS), and cytomegalovirus 
(CMV) serology. The Kaplan-Meier method was used to estimate OS and the log rank 
test to evaluate the difference between the curves. 
2.1.3 Results 
Baseline and transplant characteristics of the 105 patients are summarised in Tab. 1. 
Mean time between baseline and alloHCT was 11.6 ± 6.7 days. The 62.9% male and 
37.1% female patients had a mean age of 56.1 ± 10.9 (22-76) years. Diagnoses 
were acute leukaemias or other myeloid malignancies (76.2%; AML, MDS, ALL, CML, 
MPS) and lymphoid malignancies excluding ALL (23.8%; MM, NHL, CLL). Patients 
underwent reduced-intensity regimens [64], and peripheral blood stem cells were 
the graft in all transplantations with 76.2% having a volunteer unrelated donor. 
Mean BMI was 25.9 ± 4.1 kg/m2 , and according to age- and gender-specific percen-
tiles, 22.9% and 8.6% of the patients had low (<10th percentiles) and high (>90th 
percentiles) BMI values, respectively. Most patients (77.1%) were classified as well 
nourished and few (9.5%) as severely malnourished according to the SGA question-
naire at admission. A low overall phase angle was detected in this cohort with mean 
standardised phase angle of -1.31 ± 1.25. The probability of having positive stan-
dardised phase angle values, above age-, gender- and BMI-specific reference values, 
was unexpectedly low (12.6%).  
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Tab. 1: Patient and transplant characteristics (n = 105) 
Sex n (%) 
 male 
 female 
 
66 (62.9) 
39 (37.1) 
Age (years) 
 mean ± SD 
 min-max 
 
56.1 ± 10.9 
22 – 76 
Diagnosis n (%) 
 AML, MDS, ALL, CML, MPS 
 MM, NHL, CLL, MCL 
 
80 (76.2) 
25 (23.8) 
Conditioning regimens n (%) 
 Fludarabine, BCNU, Melphalan (FBM) 
 Fludarabine, Thiotepa (FTT) 
 Fludarabine, BCNU, Thiotepa (FBTT) 
 Busulfan, Cyclophosphamide (BC) 
 other1 
 myeloablative 
 reduced intensity 
 
66 (62.9) 
17 (16.2) 
8 (7.6) 
8 (7,6) 
6 (5.7) 
9 (8.6) 
96 (91.4) 
Remission at transplant n (%) 
 early disease (CR1, CP1, RA, RARS, 
     NHL/MM with tandem-HCT, CLL ≤2 
     therapy regimes pre-HCT) 
 advanced disease (all other stages) 
 
36 (34.3) 
 
 
69 (65.7) 
Donor status n (%) 
 related 
 unrelated 
 
25 (23.8) 
80 (76.2) 
Graft source n (%) 
 peripheral blood stem cells 
 
105 (100) 
GVHD prophylaxis 
 containing cyclosporine A (CsA)2 
 containing Certican®3 
 
95 (90.5) 
10 (9.5) 
BMI (kg/m2) 
 mean ± SD 
 min-max 
Adjusted BMI n (%) 
 
25.9 ± 4.1 
16.5-35.0 
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 <10th percentile 
 10th - 90th percentile 
 >90th percentile 
24 (22.9) 
72 (68.5) 
9 (8.6) 
SGA questionnaire n (%) 
 A - well nourished 
 B - moderately malnourished 
 C - severely malnourished 
 
81 (77.1) 
14 (18.4) 
10 (9.5) 
Standardised phase angle n (%) 
 mean ± SD 
 ≥0 
 <0 
 
-1.31 ± 1.25 
13 (12.6) 
92 (87.4) 
Abbreviations: ALL = acute lymphocytic leukaemia, AML = acute myeloid leukaemia, BMI 
= body mass index, CLL = chronic lymphocytic leukaemia, CML = chronic myeloid leu-
kaemia, CR1 = complete remission, CP1 = chronic phase, MCL = mantle cell lymphoma, 
MDS = myelodysplastic syndrome, MM = multiple myeloma, MPS = myeloproliferative 
syndrome, NHL = Non-Hodgkin’s lymphoma, RA = refractory anaemia, RARS = refrac-
tory anaemia with ringsideroblasts, SD = standard deviation, SGA = Subjective Global 
Assessment. 1 Modified regimens: melphalan (n = 1), fludarabine + melphalan (n = 2), 
fludarabine + melphalan + thiotepa (n = 1), fludarabine + thiotepa + treosulfan (n = 1), 
and total body irradiation + etoposid + cyclophosphamide (n = 1). 2 CsA/Campath (n = 
83); CsA mono (n = 1), CsA/MMF (Mycophenolate mofetil)/ATG  (Anti thymocyte globu-
lin) (n = 2); CsA/MMF (Mycophenolate mofetil)/Campath (n = 1); CsA/MTX (Meth-
otrexate)/ATG (n = 4). 3 Myfortic/Certican (n = 9), Myfortic/Certican/Campath (n = 2). 
 
Univariate and multivariate analysis of risk factors 
Overall Survival (OS). The 2-year NRM, PFS and OS rates for all patients were 
64%, 41% and 49%, respectively. Tab. 2 summarises the results of the univariate 
analysis for risk factors for 2-year OS. Nine of 17 investigated factors showed P <0.2 
in the univariate analysis and formed the initial variable set for the multivariate Cox 
regression model (Tab. 2). These included adjusted BMI (low), standardised phase 
angle (≤-2.26), recipient age (>60 years), remission status (advanced disease), KPS 
(≤80), donor status (unrelated), CMV serology (recipient positive), HLA-C and -A, -B, 
-DRB statuses (incompatible). Multivariate analysis after backward elimination re-
vealed that only an extremely low standardised phase angle (≤-2.26) (HR: 1.97; P = 
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0.043), unrelated donor (HR: 2.64; P = 0.039) and HLA-C incompatibility (HR: 2.13; 
P = 0.024) were significant independent risk factors for 2-year OS. Less significant 
associations with OS were found for low BMI (HR: 1.82; P = 0.09), older age (>60 
years) (HR: 1.78; P = 0.062) and advanced disease (HR: 1.97; P = 0.056). Patients 
classified as malnourished by the SGA questionnaire did not reveal reduced survival. 
Kaplan-Meier curves of survival in the entire follow-up period for standardised phase 
angle and adjusted BMI categories are shown in Fig. 1 and Fig. 2. 
Non-relapse Mortality (NRM). The significant multivariate analysis results for all 
nutritional markers as independent risk factors for the analysed outcomes are sum-
marised in Tab. 3 and all further significant factors are listed in the table’s legend. 
Besides low BMI (HR: 2.90; P = 0.018) as the sole nutritional marker, only unrelated 
donor (HR: 5.36; P = 0.028) were significant and high BMI (HR: 3.02; P = 0.062), 
HLA-C (HR: 2.14; P = 0.069) and HLA-A, -B, -DRB (HR: 2.37; P = 0.074) disparities 
were modestly independent risk factors for 2-year NRM.  
Relapse Mortality (RM). Multivariate analysis revealed that an extremely low stan-
dardised phase angle and advanced disease were associated with elevated HRs of 
3.18 (P = 0.017) and 4.19 (P = 0.025) for increased 2-year RM, respectively.  
Progression-free survival (PFS). Multivariate analysis revealed extremely low 
standardised phase angle (HR: 1.91; P = 0.039), advanced disease (HR: 2.46; P = 
0.025) and HLA-C disparity (HR: 2.1; P = 0.019) to be significant risks factors for 
PFS. A trend toward significance was found for unrelated donor (HR: 2.15 P = 
0.053). 
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Tab. 2: Pretransplant risk factors for 2-year OS after alloHCT (Cox re-
gression analysis, n = 105) 
Variable  Value HR  95% CI P value 
Univariate Cox regression analysis 
Weight change 
over previous 6 
months 
loss  0.97 0.55-1.72 0.93 
low 1.75 0.93-3.33 0.08 
Adjusted BMI 
high 1.25 0.48-3.24 0.64 
SGA questionnaire 
malnourished (B, 
C) 
1.38 0.73-2.61 0.32 
Stand. phase angle ≤-2.26 1.74 0.93-3.26 0.08 
Recipient age >60 years 2.04 1.15-3.61 0.01 
Recipient gender male 0.95 0.53-1.71 0.87 
Donor age >40 years 0.96 0.54-1.71 0.90 
Recipient:donor male:female 0.86 0.45-1.66 0.66 
Diagnosis lymphatic 0.78 0.39-1.58 0.50 
Remission status advanced disease 1.86 0.97-3.59 0.06 
Donor status unrelated 2.89 1.23-6.82 0.02 
Karnofsky Perform-
ance Status 
≤80 1.66 0.92-2.98 0.09 
HLA-C incompatible 2.07 1.11-3.87 0.02 
HLA-A, -B, -DRB incompatible 1.88 0.84-4.21 0.13 
Conditioning1 reduced 
not esti-
mable 
- - 
HCT-CI >3 points 0.99 0.56-1.76 0.98 
CMV serology     recipient positive 0.65 0.36-1.14 0.13 
Multivariate Cox regression analysis after backward elimination2 
high 2.22 0.81-6.02 0.12 
Adjusted BMI 
low 1.82 0.91-3.65 0.09 
Stand. phase angle ≤-2.26 1.97 1.02-3.81 0.043 
Recipient age >60 years 1.78 0.97-3.28 0.062 
Remission status advanced disease 1.97 0.98-3.94 0.056 
Donor status unrelated 2.64 1.05-6.63 0.039 
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HLA-C incompatible 2.13 1.11-4.10 0.024 
Abbreviations: BMI = body mass index, CI = confidence interval, CMV = cytomegalovi-
rus, HCT-CI = Haematopoietic Cell Transplantation Comorbidity Index, HLA = human leu-
kocyte antigen, HR = hazard ratio, KPS = Karnofsky Performance Status. 1 No events 
occurred in the myeloablative group. 2 Multivariate model was applied, including those 
factors with univariate P <0.2 as an initial variable set and performing backward elimina-
tion, retaining factors if P <0.1. 
 
Tab. 3: Relevant results of multivariate Cox regression analysis of nutri-
tional markers as risk factors for 2-year outcome (OS, NRM, RM, PFS) 
among patients undergoing alloHCT [n=105, HR (95% CI), P value] 
Variable OS1 NRM2 
adjusted BMI 
low 
 
high 
 
1.82 (0.91-3.66), 0.095 
 
- 
 
2.90 (1.20-7.03), 0.018 
 
3.02 (0.95-9.64), 0.06 
SGA questionnaire  
malnourished (B, C) 
 
- 
 
- 
Stand. phase angle  
extremely low (≤-2.26) 
 
1.97 (1.02-3.81), 0.043 
 
- 
Variable RM3 PFS4 
adjusted BMI 
low 
high 
 
- 
- 
 
- 
- 
SGA questionnaire  
malnourished (B, C) 
 
- 
 
- 
Stand. phase angle 
extremely low (≤-2.26) 
 
3.18 (1.23-8.27), 0.017 
 
1.91 (1.00-3.50), 0.039 
Abbreviations: CI = confidence interval, HR = hazard ratio, NRM = non-relapse mortality, 
OS = overall survival, PFS = progression-free survival, RM = relapse mortality, SGA = 
Subjective Global Assessment. 1 Detailed results are shown in Tab. 2. 2 Unrelated donor: 
5.36 (1.20-24.04), 0.028; trend toward significance: HLA-C disparity: 2.14 (0.94-4.88), 
0.069; HLA-A, -B, -DRB disparity: 2.37 (0.92-6.09), 0.074. 3 Advanced disease: 4.19 
(1.19-14.71), 0.025. 4 Advanced disease: 2.46 (1.3-4.7), 0.006; HLA-C disparity: 2.1 
(1.1-4.1), 0.019; trend toward significance:  unrelated donor: 2.15 (1.13-4.09), 0.053. 
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Fig. 1: Survival distribution according to the standardised phase angle. 
 
Fig. 2: Survival distribution according to the adjusted BMI categories. 
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2.1.4 Discussion 
The primary purpose of this study was to investigate nutritional markers as inde-
pendent risk factors for major long-term outcomes after alloHCT. To the best of our 
knowledge, this is the first study to evaluate phase angle as a risk factor in these 
patients. 
Patients with extremely low pretransplant standardised phase angles had a higher 
risk of death in the first 2 years after alloHCT. A reduced standardised phase angle 
was one of the few independent risk factors for 2-year OS besides unrelated donor 
and HLA-C incompatibility. Death was caused by relapse, as the patients with an ex-
tremely low phase angle had a risk of RM three times higher than those with higher 
phase angles. Furthermore, this parameter correlated significantly with PFS. The two 
most influential pretransplant risk factors identified in this study and associated with 
similarly increased HRs for three of four outcomes (OS, RM and PFS) were an ex-
tremely low standardised phase angle and advanced disease, respectively. The phase 
angle is one of the raw data from bioelectrical impedance analysis, a quick, 
non‐invasive and safe method for evaluating a patients’ body composition. It is 
known to be a valid independent prognostic factor for overall survival in patients re-
ceiving chemotherapy [53,54,18,51,60]. Reduced phase angle can be a result or the 
combination of either body cell mass loss (especially muscle mass via prolonged 
physical inactivity), cell membrane weakness, and increased body water displace-
ment into extracellular space [65,51], which are the main characteristic changes 
triggered by malnutrition. Although the exact biological relevance of the phase angle 
remains unclear, previous studies report its association with physical functions such 
as handgrip strength, peak expiratory flow, and physical activity [65,66,51]. Consid-
ering that the most effective countermeasure against skeletal muscle atrophy is 
physical training combined with protein-rich nutrition [67-69], it is worth considering 
whether physical training together with the appropriate nutritional support before 
admission would improve both phase angles and outcomes after alloHCT in patients 
with reduced phase angles.  
Of the other nutritional parameters considered, only underweight and overweight, 
according to age- and gender-specific BMI percentiles (≤10th and ≥90th percentile), 
demonstrated associations with increased risk of NRM that were not directly linked to 
the other risk factors considered here. Low BMI also correlated weakly with overall 
survival. Consistent with our results having observed increased NRM in patients un-
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dergoing alloHCT with low BMI, Le Blanc et al. [8] demonstrated increased NRM in 
patients with BMI <20 kg/m2. Similar outcomes also have been observed after 
autologous HCT in underweight adults [70,71]. The literature, however, is controver-
sial about the relationship between BMI and outcome after alloHCT. Low BMI was 
found to be associated with decreased OS [72,8,73], decreased PFS [8], and later 
engraftment [74] after alloHCT. On the other hand, Fleming et al. [7] showed that 
high BMI was related to decreased OS (RM and NRM causes were equally responsi-
ble) in alloHCT. Contradictory to these results, Nikolousis et al. [10] reported that 
high BMI did not adversely affect either OS or PFS, showing however that high BMI 
had a significant impact on infection rates and duration of hospitalisation. One possi-
ble explanation for the worse outcomes observed in obese patients after conditioning 
chemotherapy followed by alloHCT is altered pharmacokinetics of chemotherapeutic 
agents compared to non-obese patients [70]. A principal pharmacokinetics parame-
ter is volume of distribution in terms of the loading dose, which changes in the larger 
absolute lean body and fat masses in obese patients [75,76]. Furthermore, obesity 
may implicate impaired renal function [77,78] and hepatic drug metabolism due to 
liver damage induced by fatty infiltrations [79]. These factors may lead to the over-
dosage of chemotherapeutics in obese patients and thus a higher risk of NRM. On the 
other hand, undernutrition (low BMI) is known to be associated with many adverse 
outcomes [80], including depression of the immune system, which increases the like-
lihood of developing infections [81]. Le Blanc et al. [8] confirmed that alloHCT pa-
tients with low pretransplant BMI were affected by bacterial septicaemia significantly 
more often and required more granulocyte transfusions. However, Nikolousis et al. 
[10] reported results showing higher infection rates in overweight patients after 
alloHCT. Although the data from the literature are inconsistent and the precise 
pathophysiology of adverse outcomes in alloHCT patients with low or high body 
weight remains largely unknown, patients not falling within ideal weight ranges may 
be either at a higher risk of relapse mortality via insufficient dosage, or of NRM via 
drug toxicity. 
Finally and surprisingly, we identified no association with any of the outcomes we 
investigated for the two main and most widely-used parameters in the screening and 
assessment of nutritional status (and valid predictors of worse outcome in cancer 
patients9, namely weight changes over the previous six months [82] and the SGA 
questionnaire [17,19,20]. This reveals that the significance of the phase angle and 
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BMI as risk factors is independent of weight dynamics before admission to transplan-
tation. 
A limitation of our study concerns the cut-off value defined as the lower quartile 
(25th percentile) of a standardised phase angle in our study sample, reducing the 
external validity of our results [62,60]. Therefore, Paiva et al. [83] propose using a 
cut-off value of the 5th percentile of a healthy reference population in studies. Our 
patients tended to present extremely low phase angle values at admission, making 
their proposed cut-off unusable for our analysis and obliging us to compare patients 
with extremely low values with those with low to normal values. A further limitation 
to consider has to do with our study's comparability with other studies - that we are 
the first to have categorised each BMI value in terms of age- and gender-specific BMI 
percentiles. We are convinced that this standardisation is the most suitable means of 
making heterogeneous cohorts comparable and of overriding the weakness of the 
fixed WHO classification, which fails to consider dynamic changes and gender-specific 
differences in body weight during the entire lifespan [12]. However, as all of the pub-
lications we have considered used different BMI risk categories, they are difficult to 
compare. 
In summary, our results demonstrate for the first time that the pretransplant phase 
angle, here presented as a standardised value, was an independent predictor for 2-
year OS, NRM and PFS in patients undergoing alloHCT. In line with other studies, BMI 
adjusted for age and gender emerged as an independent risk factor for OS and NRM. 
Both nutritional markers performed better than malnutrition according to the SGA 
questionnaire, weight history and numerous generally-accepted risk factors; they 
were the only significant prognostic values for outcome in our cohort beyond HLA-C 
compatibility, donor, and remission status. 
Most of the many risk factors before alloHCT cannot be modified. On the other hand, 
BMI and phase angle are theoretically modifiable during the often lengthy treatment 
period before transplantation. Further investigation is necessary to demonstrate 
whether or not the phase angle can be increased by strategies that enhance muscle 
mass via physical training together with nutritional support, and whether this ap-
proach can lead to beneficial effects on outcome after alloHCT. 
 
Original research articles                           Course of nutritional status     18 
2.2 Longitudinal follow-up of nutritional status and its 
influencing factors in adults undergoing allogeneic 
haematopoietic cell transplantation 
Course of nutritiona l sta tus 
2.2.1 Introduction 
AlloHCT is a potentially curative treatment in patients with diseases of the blood and 
bone marrow or certain types of cancer [1]. However alloHCT is a risky procedure 
that can cause many complications ranging from mucositis, infections, and graft-
versus-host disease (GVHD) to treatment or progression-related mortality [2-4]. 
AlloHCT-associated complications and their medical treatments often cause tremen-
dous changes in body composition, especially trough-disturbed muscle metabolism 
[5,6]. Furthermore, under- and overweight patients are at an increased risk in-
creased risk for complications, non-relapse mortality, and overall survival after al-
loHCT [7-10]. 
To date, few studies have assessed nutritional status before alloHCT, and most of 
them only recorded body mass index (BMI) as a potential risk factor for survival [7-
10]. Except for one report by Kyle et al. [11] on the  development of lean body 
mass, there was until now no longitudinal data on nutritional status and body com-
position in the early post-transplant period. 
There are now many nutritional parameters available and validated for cancer 
patients. The phase angle is one of them. It is measured by bioelectrical impedance 
analysis and reflects cell membrane function [50] and indirectly, the body’s muscle 
mass [51]. It is an established parameter for diagnosing malnutrition, and a useful 
prognostic marker in many clinical conditions [52] including several types of cancer 
[53,54,18,55]. The Subjective Global Assessment (SGA) questionnaire according to 
Detsky et al. [13] is another means of demonstrating the best combination of sensi-
tivity and specificity in identifying complications related to malnutrition [56], making 
the SGA questionnaire a validated tool in cancer patients with which to evaluate nu-
tritional status [20]. 
The main objective of this prospective study was to assess the nutritional status in 
patients before alloHCT and its course during the early post-transplant period until 
day +100 via weight change before admission, body mass index (BMI) normalized 
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for gender and age, the SGA questionnaire, and the phase angle normalized for gen-
der, age, and BMI. To deepen understanding and develop future preventive and 
interventional approaches, we also investigated the impact of influencing factors on 
the body weight course during the early post-transplant period.  
2.2.2 Subjects and methods 
Study population  
Adult patients with haematological malignancies admitted for alloHCT to our institu-
tion at University Medical Centre Freiburg between 2008 and 2010 were eligible to 
enter this prospective survey. The study protocol was approved by our local Ethics 
Committee, and all patients provided informed consent.  
Study design and data collection 
Nutritional status at admission and on days +30 and +100 after alloHCT was as-
sessed in 105 patients by measuring body weight, performing bioelectrical imped-
ance analysis, and assessing nutritional status classification according to the SGA 
questionnaire. At admission we recorded weight changes in the previous six months, 
body height, HCT-Comorbidity Index (HCT-CI) [84] and Karnofsky Performance 
Status (KPS). Moreover, we assessed at each time point the actual portion size of 
food intake (100%, 75%, 50%, ≤25% of usual size) and relevant discomfort 
(anorexia, diarrhoea, taste disturbance, fatigue) graded as: no, mild, moderate or 
severe. Oral mucositis classified by the WHO oral toxicity scale [85] and infections as 
early toxicities and duration of parenteral nutrition were assessed until day +30. 
Maximum grade of acute graft-versus-host disease (aGVHD) (°0-°IV) and all further 
medical data were collected from hospital records. Nutritional interventions followed 
standard institutional clinical practice. 
Adjusted body mass index (BMI): Considering the age and gender dependencies 
of BMI, we used current and representative German BMI percentiles to categorise 
each value as low (<10th percentile), normal (10-90th percentile) or high (>90th 
percentile) according to age- and gender-specific BMI percentiles [12].  
Subjective Global Assessment (SGA): The SGA questionnaire according to 
Detsky et al. [13] is a simple, validated bedside tool for use in cancer patients with 
which to subjectively evaluate nutritional status, mainly according to weight-loss his-
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tory, relevant symptoms impairing nutrition intake, and a basic physical examination 
requiring no equipment. Patients were classified as well nourished (SGA-A), moder-
ately malnourished (SGA-B), and severely malnourished (SGA-C)., the SGA ques-
tionnaire classification has been shown to be associated to quality of life [17], length 
of hospital stay [19] and survival [57]. 
Standardised phase angle: Bioelectrical impedance analysis is a validated, non-
invasive, portable method to estimate body composition with specific algorithms 
based on the electrical properties of body tissues [58]. Bioelectrical impedance 
analysis is useful in assessing and monitoring nutritional status [50,59]. The phase 
angle, one of the raw data obtained from bioelectrical impedance analysis measure-
ments and therefore independent from the equipment and internal algorithms used, 
has proved to be a good prognostic, nutritional, and membrane cell function marker 
in various diseases [53,60,61,55]. Sex-, age-, and BMI-specific reference values of 
the phase angle from a large healthy German population [14] were used to calcu-
lated the standardised phase angle according to the formula standardised phase 
angle = (phase angle - phase angleref)/SDref, where phase angleref and SDref are the 
age-, sex- and BMI-specific mean and standard deviation of a healthy population, 
respectively. Positive values are expected for healthy individuals [62]. The transfor-
mation of phase angle values into standardised values (Z-score) allows us to quantify 
individual deviations from sex-, age-, and BMI-specific population averages and to 
compare subjects from a heterogeneous group. Furthermore, Norman et al. [51] 
showed that this standardisation clearly enhances the phase angle's predictive 
power. Our analysis employed a multifrequency device (Body Scout instrument, 
Fresenius Medical Care, Germany) under standardized conditions [63]. 
Statistical analysis 
We used IBM SPSS 19 (IBM, NY, USA) and SAS 9.2 (SAS Institute Inc., Cary, NC, 
USA) software for statistical analysis. Mean and standard deviations (SD) were used 
in case of approximately symmetric distributions, and when useful min-max as well. 
Paired t-tests were used to analyze differences over time in continuous variables. To 
examine the impact of potential influencing factors on the body weight course from 
days +30 until day +100, we used linear regression models with change in BMI as 
the dependent variable. First, univariate models were employed for a preliminary 
assessment of single factors. Then, a multivariate model was constructed with those 
variables showing a univariate P <0.1. Results of the linear regression model are 
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presented as parameter estimates for the regression coefficients with accompanying 
2-sided 95% confidence intervals (CI). For continuous independent variables (e.g. 
BMI at day +30), the regression coefficient represents the increase in serum 
25(OH)D3 concentration for a one unit increase in the respective continuous variable. 
For binary independent variables (all other variables), the regression coefficient de-
scribes the difference in BMI course between two groups. 
2.2.3 Results 
Patient and transplant characteristics 
Baseline and transplant characteristics of the 105 patients are summarised in Tab. 1 
on page 9. The 62.9% male and 37.1% female patients had a mean age of 56.1 ± 
10.9 (22-76) years. The diagnoses were acute leukaemias or other myeloid malig-
nancies (76.2%; AML, MDS, ALL, CML, MPS) and lymphoid malignancies excluding 
ALL (23.8%; MM, NHL, CLL). Patients were treated with reduced-intensity regimens 
[64] and peripheral blood stem cells were the graft in all transplantations with a vol-
unteer unrelated donor in 76.2%. Advanced disease was diagnosed in 65.7% of the 
patients at transplantation. Mean time between baseline and alloHCT was 11.6 ± 6.7 
days, day +30 was 28.6 ± 2.9 days, and day +100 was 99.4 ± 6.5 days after al-
loHCT.  
Baseline nutritional status 
Different aspects of baseline nutritional status are shown in Fig. 3. At admission, 
most (77.1%) of the patients were classified as well nourished and few (9.5%) as 
severely malnourished according to the SGA questionnaire. However, 23.8% of the 
patients reported significant weight loss during the last six months of 5-10% 
(10.5%) and >10% (13.3%), respectively. Mean BMI was 25.9 ± 4.1 (16.5-35.0) 
kg/m2 and according to the WHO [86] 1.9% and 54.3% were classified as under-
weight (≤18.5 kg/m2) and overweight (≥25 kg/m2), respectively. In contrast, ab-
normal age- and sex-adjusted BMI values (<10th, >90th percentiles) were found in 
31.5%, with 22.9% having low and 8.6% high values. An overall low phase angle 
was detected in this study population with a mean standardised phase angle of -1.31 
± 1.25. The probability of having positive standardised phase angle values, and 
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phase angle values above age-, gender- and BMI-specific reference values, was un-
expectedly low (13.3%) in this cohort. 
 
 
Fig. 3: Baseline nutritional status characteristics in 105 patients undergoing alloHCT just 
before conditioning chemotherapy started. Weight change over previous six months; age- 
and sex-adjusted BMI; Subjective Global Assessment (SGA) questionnaire and standard-
ized phase angle (SPA) were classified. 
 
Course of nutritional status 
Longitudinal data (N = 78 patients) of weight, represented as BMI, and of standard-
ised phase angle are shown in Fig. 4, revealing that BMI decreased significantly      
(P <0.0001) in both measured periods from 26.1 ± 3.8 kg/m2 at admission to 23.2 
± 3.0 kg/m2 at day +100 by 11% in total. In other words, this represents a total 
weight loss of 8.6 ± 5.7 kg during the study period. Simultaneously, the patients 
experienced an extraordinarily high 74.3% drop in the standardised phase angle dur-
ing the first 40 days after admission (P <0.0001). We observed a trend towards fur-
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ther standardised phase angle deterioration during the rehabilitation period after 
ward discharge till day +100 (P = 0.06). 
 
 
Fig. 4: Course of mean BMI (solid line) and standardised phase angle (SPA) (dashed 
line) during the study period (baseline, day +30 and day +100 after alloHCT). Figure 
represents data sets of 78 patients and error bars are +/- 1 SD. *** significant decrease 
P <0.0001. † nearly significant decrease P = 0.06 (paired t-test). 
 
Impact of factors influencing the body weight course 
As body weight loss remains significant during the rehabilitation period after ward 
discharge, we investigated the impact of a variety of potential influencing factors of 
body weight. We used change in body mass index (BMI), weight normalized for 
height, as the dependent variable. All the influencing factors for univariate analysis 
we considered are listed in Tab. 4. In univariate analysis, clinically-relevant aGVHD  
(P = 0.02) and anorexia (P = 0.02) were significantly associated with increased loss 
of BMI. A multivariate regression model was constructed with those variables show-
ing a relationship (P <0.1) to BMI course. Only HCT-CI and BMI on day +30 were 
added in this model and after multivariable adjustment, clinically-relevant aGVHD 
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(parameter estimate -1.43; 95% CI: -2.61, -0.26; P = 0.02) and increasing grades 
of anorexia (parameter estimate -0.52; 95% CI: -0.99, -0.06; P = 0.03) were identi-
fied as independent influencing factors of BMI loss in the investigated period. 
 
Tab. 4: Results of regression analysis investigating potential influencing 
factors of BMI course from day +30 to day +100 in patients undergoing 
alloHCT (n = 75) 
Influencing factor Unit Parameter estimate 
(95% CI) 
P 
value 
Univariate analysis  
Recipient age ≥60 vs <60 -0.42 (-1.57, 0.72) 0.47 
Recipient gender male vs female 0.01 (-1.17, 1.18) 0.99 
Diagnosis 
lymphoid  vs myeloid 
malignancies 
-0.27 (-1.70, 1.15) 0.70 
Donor status unrelated vs related 1.26 (0.02, 2.51) 0.047 
HCT-CI high vs low risk 0.95 (-0.18, 2.08) 0.098 
Conditioning chemo-
therapy 
ablative vs reduced in-
tensity 
-0.72 (-2.52, 1.08) 0.43 
HLA A, B, DRB 
incompatible vs com-
patible 
-1.15 (-3.16, 0.85) 0.25 
Remission status at 
admission 
advanced vs early dis-
ease 
-0.31 (0.87, -1.49) 0.60 
Karnofsky Perform-
ance Status 
≤80 vs >80 -1.15 (-3.50, 1.19) 0.33 
BMI at day +30 kg/m2 -0.13 (-0.29, 0.02) 0.09 
Serum CRP at day 
+30 
mg/l -0.01 (-0.04, 0.01) 0.29 
aGVHD maximal 
grade till day +100 
II°-IV° vs °0-°I  1.40 (0.23, 2.58) 0.02 
Actual portion size 
of food intake at day 
+30 
 ≤75% vs >75%  -0.14 (-0.67, 0.40) 0.61 
Anorexia at day +30 grades 2-3 vs 0-1¹ 1.04 (-0.09, 2.18 0.07 
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Diarrhea at day +30 grades 2-3 vs 0-1 0.67 (-0.87, 2.22) 0.39 
Taste disturbance at 
day +30 
grades 2-3 vs 0-1 0.84 (-0.29, 1.99) 0.14 
Fatigue at day +30 grades 2-3 vs 0-1 0.85 (-0.31, 2.02) 0.15 
Multivariate analysis  
Donor status unrelated vs related 0.76 (-0.50, 2.03) 0.23 
HCT-CI high vs low risk 0.91 (-0.17, 1.99) 0.10 
BMI at day +30 kg/m2 -0.10 (-0.25, 0.05) 0.19 
aGVHD II°-IV° vs °0-°I 1.46 (0.26, 2.66) 0.02 
Anorexia grades 2-3 vs 0-1 1.07 (-0.04, 2.18)  0.058 
Abbreviations: aGVHD = acute graft-versus-host disease, BMI = body mass index, CI = 
confidence interval, CRP = C-reactive protein, HCT-CI = Hematopoietic Cell Transplanta-
tion Comorbidity Index, HLA = human leukocyte antigen. ¹ grades 2-3 vs 0-1 = grades 
(moderate and severe) vs (no and mild)  
 
2.2.4 Discussion 
We herein present a longitudinal follow-up of nutritional status in adults undergoing 
alloHCT, and for the first time a multivariate linear regression model investigating the 
impact of factors on the course of body weight during the early rehabilitation period. 
When adjusted BMI (78% in normal range) and the SGA questionnaire (77% well 
nourished) before alloHCT are considered, our findings on nutritional status in pa-
tients with haematological malignancies are consistent with other reports showing 
that the majority of these patients is well nourished [19,87,11,88]. However, 
approximately half of the patients experienced unintentional weight loss over the 
previous six months before alloHCT, revealing that changes in body composition were 
a frequent condition in these patients - a fact often overlooked when using BMI as 
sole tool in the determination of nutritional status. 
According to the adjusted BMI classification, ten times more patients were classified 
as underweight according to age- and gender-specific percentiles than when refer-
ring to the standard WHO classification. The fixe WHO classification of e.g. normal 
weight (18.5-25 kg/m2) does not consider the dynamic changes and gender-specific 
differences in body weight over the entire lifespan [12], nor does it take into account 
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that when considering all-cause mortality, optimal BMI varies by age and sex 
[89,90]. We therefore recommend that, when the BMI is used in the context of nutri-
tional assessment, that it be employed to compare BMI calculations with age- and 
gender-specific BMI percentiles of an appropriate reference population. 
Further, on closer inspection with bioelectrical impedance analysis measurements, we 
detected positive standardised phase angle values (expected in well-nourished, 
healthy individuals) in only 13.3% of our patients despite their overall normal BMI. 
This reveals that the phase angle, which is a valid nutritional marker and independ-
ent indicator of survival for patients receiving chemotherapy [53,54,18,51,60], was 
extremely low in this cohort. A reduced phase angle can be the result of or the com-
bination of either body cell mass loss (especially muscle mass via prolonged physical 
inactivity), cell membrane weakness, and increased body water displacement into 
extracellular space [65,51], which are the main characteristic changes triggered by 
malnutrition. 
Explanations for this completely different picture provided by the phase angle com-
pared to BMI and the SGA questionnaire are that BMI is a limited measure of nutri-
tional status, giving us only information on low or high fat mass; the SGA question-
naire’s main classification criterion is weight change over the previous weeks. A 
major limitation of these quick tools (BMI, SGA questionnaire) is that relevant 
changes in body composition (e.g. loss of fat-free mass, mainly due to muscle atro-
phy) can be disguised by an increase in fat mass or fluid retention leading to stable 
overall weight [91]. This factor is highlighted by a small study in alloHCT patients 
showing significant fluid shifts to extracellular space, along with significant body cell 
mass loss till day +30, whereby body weight and fat mass remained constant [92].  
Regarding changes in nutritional status during the early post-transplant period, we 
demonstrate convincingly that the losses of body weight and phase angle are espe-
cially high in the period between conditioning therapy until day +30 (a 40-day inter-
val), and that they do not cease during the two months of rehabilitation after hospi-
tal discharge, although we did notice that this deterioration was somewhat 
alleviated. Lenssen et al. [9] reported that the frequency of depleted muscle 
reserves rose independently of weight changes during the first post-transplant year 
in alloHCT recipients. Moreover, Kyle et al. [11] even showed that any loss of weight 
and lean body mass experienced during the immediate post-transplant period (re-
flecting muscle mass amongst other factors) is not regained during the first year. 
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Possible explanatory models include persistent discomfort affecting oral intake and 
intestinal distress during that period, especially true in patients with chronic GVHD 
involving the oral mucosa [9], decline in physical activities for up to one year after 
transplantation [9], a negative energy balance due to hypermetabolism, and the 
catabolic effects on skeletal muscle exerted by medication with corticosteroids [5,6] 
as well as immunosuppressive drugs [93,94]. 
Summarising these results, changes in body weight are not sensitive enough to de-
tect relevant changes in body composition, as the loss of fat-free mass is often 
masked by an excess of fat mass and/or extracellular fluid. This brings into focus the 
proposal that body composition measurements such as bioelectrical impedance 
analysis, muscular strength, and/or mid-arm muscle circumference are indicated for 
the assessment of nutritional status in these patients. Weight loss during the early 
post-transplant period from day +30 until day +100 rose significantly due to the 
severity of anorexia and aGVHD ≥°II, both predominant alloHCT-associated compli-
cations [95-97]. Depending on the organs affected by aGVHD (≥°II), it can alter nu-
tritional status directly via food intake or nutrient uptake or indirectly via corticoster-
oid therapy, both of which have negative effects on muscle metabolism [5].  
A limitation of this study relates to the lack of an exact record of the duration and 
quantity of corticosteroid medication during the study period, which is known to 
promote muscle atrophy and should therefore be included in future regression 
models.  
In conclusion, we found as have others patients in good overall nutritional condition 
before alloHCT using quick screening tools for malnutrition such as BMI and the SGA 
questionnaire. However, upon closer inspection of their nutritional status, we 
observed unintentional weight loss before alloHCT to be a frequent condition, detect-
ing many more underweight patients by using age- and gender-specific BMI classifi-
cation, and overall low phase angle values at admission. The deterioration in our 
cohort’s nutritional status was significant during the early post-transplant period, in 
spite of our clinic’s internal standards of regular diet counselling, parenteral nutrition 
when needed, and high energy supplements ad libitum, combined with fast mobilisa-
tion and light physical activities. Furthermore, we identified anorexic patients and 
those with clinically-relevant aGVHD to be at an increased risk of decline in nutri-
tional status during early rehabilitation. Beyond body weight measurements, our 
results reveal the key role of more reliable methods with which to identify those pa-
Original research articles                           Course of nutritional status     28 
tients who need individually-adapted nutritional interventions and for monitoring the 
response to such treatment. Further studies are necessary to investigate new nutri-
tional intervention strategies combined with physical training capable of preventing 
such deterioration in nutritional status during the early post-transplant period.     
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2.3 Role of antioxidants in buccal mucosa cells and plasma on the 
incidence and severity of oral mucositis after allogeneic 
haematopoietic cell transplantation 
Role of AOX in o ral mucositis 
2.3.1 Introduction 
Oral mucositis (OM) is an adverse effect of chemotherapy preceding HCT [21]. Con-
sequences of OM range from soreness and painful ulcerations to malnutrition and 
life-threatening infections, and it is associated with significantly worse clinical and 
economic outcomes [22,23]. To date there is no preventative or treatment therapy 
for OM, and little is known of risk factors for its occurrence [24,25].  
A major stimulus for the initiation of OM is the induction of reactive oxygen species 
[24] which result in tissue damage triggered by chemotherapy and/or radiation 
[26,27]. In addition to the endogenous antioxidative system, exogenous antioxidants 
(AOX) such as α-tocopherol (vitamin E), ascorbic acid (vitamin C), and ß-carotene 
scavenge free radicals and may therefore reduce incidence and severity of OM 
[28,29]. A small clinical trial in patients suffering from chemotherapy-induced OM 
showed that vitamin E applied locally induced a significantly more rapid resolution of 
lesions compared to the placebo group [98]. 
AOX are usually measured in plasma, but this does not necessarily provide evidence 
of the supply in the target tissue, because the plasma concentrations of several 
micronutrients are under homeostatic control. Therefore, the determination of their 
concentrations at the main site of action, namely the buccal mucosal cells (BMC) as 
in this study, could be more reliable [28,30]. 
To the best of our knowledge, this is the first report investigating prospectively the 
association between AOX status and the risk of developing OM in patients undergoing 
alloHCT after chemotherapy-containing conditioning regimens. Our primary objective 
was to assess the impact of plasma vitamin E status before alloHCT on the occur-
rence of ulcerative OM. Additional objectives included the influence of vitamin E con-
centrations on BMC, vitamin C and ß-carotene concentrations in BMC and plasma on 
the incidence and severity of OM. Furthermore, we investigated the influence of dif-
ferent maximum OM grades on the duration of parenteral nutrition and neutropenia, 
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the use of opioid analgesia, incidence of acute graft-versus-host disease (aGVHD) 
and herpes simplex virus (HSV) infections, respectively.  
2.3.2 Patients and methods 
Study population  
This observational study began at the end of 2008 and adult patients with haemato-
logical malignancies admitted for alloHCT to our institution at University Medical Cen-
ter Freiburg and receiving fludarabine-based, reduced-intensity conditioning regi-
mens were eligible. The exclusion criterion was the presence of OM at baseline. The 
study protocol was approved by our local Ethics Committee, and all patients provided 
informed consent. 
Study design and data collection 
Samples of blood and BMC were collected at admission for assessing AOX status 
(vitamin E, C, and ß-carotene), and baseline characteristics were recorded. OM was 
assessed every second day, starting five days before alloHCT, and until discharge of 
the patients or day +30 after transplantation. We assessed OM daily only during the 
period in which OM is most likely to be maximal [22] (between days +4 and +10). To 
classify OM we used the WHO oral toxicity scale [85], which summarizes OM-related 
symptoms, signs, and functional disturbances on a five-point global scale. No or 
mild, ulcerative and severe OM were defined as WHO scale grades 0-I, II-IV and   
III-IV, respectively. Consistent quality of OM assessment was assured, as the three 
investigators conducting the study were supervised and trained by the same physi-
cian. In addition, the patients themselves estimated the intensity of OM-specific 
symptoms (dysphagia, diarrhoea, xerostomia and pain in the oral cavity) using a 4-
point scale ranging from 0 (no symptoms) to 4 (severe symptoms).  
All further data, including medical data, infections in the oral cavity, duration of par-
enteral nutrition, and maximum grade of oral/enteral aGVHD were collected from the 
hospital records. OM management followed standard institutional clinical practice, 
including oral care, topical antimicrobials, ice and analgesic support. Prophylaxis 
therapy consisted of an oral mouthwash with Salviathymol™ used 3 to times a day. 
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Sampling BMC and blood  
BMC were collected using a kit from Day-med-concept GmbH, Berlin, Germany. Sub-
jects first had to rinse their mouths with water thoroughly to remove food particles 
and then brush the inner lining of their cheeks with a soft toothbrush twenty times, 
twice on each side. The toothbrush was washed in 25 ml NaCl solution (0.9%) gently 
after each brushing. The samples were then centrifuged at 1600 rpm for 3 minutes. 
The supernatant was discarded; the cells were completely resuspended in rinsing 
solution (phosphor float 0.15% w/v) and centrifuged again at 1800 rpm for 3 min-
utes. After removal of the supernatant fraction, the stabilizing solution (heat-
sensitive reducing agent 0.09% w/v) was added; and the cells were resuspended 
and stored. 
The blood samples were taken into EDTA-Monovettes and stored in the dark for 10 
minutes; the tubes were then centrifuged at 3000 rpm for 10 minutes at 4 °C. 200 µl 
from the resulting plasma were transferred into a 1.7 ml reagent tube with buffer 
solution (reducing agent) for vitamin C analysis and 500 µl in an empty reagent tube 
for vitamin E and ß-carotene analysis. All samples were frozen at -80 °C and shipped 
every 3 to 4 months on dry ice to the analyzing company. The AOX in BMC and 
plasma (pmol/µg DNA) of the samples were measured by BioTeSys GmbH (Esslingen, 
Germany) using an accredited RP-HPLC method according to DIN EN ISO/IEC 17025. 
The reference values are based on a statistical distribution reflecting the 25th and 
75th percentile of a data set covering analysed BMC samples over one year.  
Sample size calculation and statistics 
This study was designed to detect a difference of 20% (6,1 µmol/L) in plasma vita-
min E concentrations between the no or mild and ulcerative OM groups with a power 
of 80% with a two-sided t-test at a significance level of 5%. The assumed standard 
deviation was 9,3 µmol/L in the study population, derived from data on the vitamin E 
status of German adults [99]. No or mild OM and ulcerative OM groups were not ex-
pected to be equally large, as the mean ulcerative OM risk is 54% according to pre-
vious investigations. The expected ratio of no or mild to ulcerative OM groups was 
0.85 and the resulting sample size was 76 patients in total. The duration of the study 
was scheduled for 14 months.  
For descriptive data analyses, all values are presented as means ± SDs and if useful 
(min - max) when distributed normally or when not as median (min - max). Two 
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sample t-tests or Wilcoxon rang-sum tests were used for group comparisons of con-
tinuous variables distributed normally or not, respectively. Chi-square tests were 
used to analyze categorical variables between two groups. Pearson’s correlation was 
calculated to assess the relation between variables. 
For investigating the interactions of any one AOX in the antioxidative network, we 
compared patients with all plasma AOX in or above the normal range (AOX-
sufficiency group) to patients with at least one suboptimal plasma AOX (AOX-
inadequacy group) with regard to our outcome parameters. For statistical analysis 
we used SPSS version 16.0 (SPSS Inc, Chicago, IL, USA). 
2.3.3 Results 
Patient and transplant characteristics 
After the defined study period, we enrolled 74 instead of the planned 76 patients. 
Four patients were excluded, two because the HCT had to be rescheduled, one pa-
tient died before finishing the study, and one required intensive medical care during 
the study and was no longer available. Baseline and transplant characteristics of the 
70 evaluable patients are summarised in Tab. 5. The 47 (67%) male and 23 (33%) 
female patients with a mean age of 58.2 ± 10.2 (26-76) y had a mean body mass 
index (BMI) of 26.0 ± 4.0 (19-35) kg/m2. The diagnoses were acute leukaemias or 
other myeloid malignancies (81.5%; AML, MDS, ALL, CML, MPS) and lymphoid ma-
lignancies excluding ALL (18.5%; MM, NHL, CLL, MCL). 
Peripheral blood stem cells were the graft in all transplantations with a volunteer un-
related donor in 70%. All patients were treated with fludarabine-based, reduced-
intensity regimens, mainly fludarabine, carmustine (BCNU) and melphalan (FBM) in 
71.4% [64]. Sixteen (33%) of the patients received additional preconditioning che-
motherapy because of high blast counts in peripheral blood or bone marrow. Ad-
vanced or active disease was diagnosed in 58 (82.9%) patients, and 12 (17.1%) 
were transplanted for early disease. Three (4.3%) had undergone one previous al-
logeneic and 9 (12.9%) one or more previous autologous HCT. 
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Tab. 5: Patient and transplant characteristics (n = 70) 
Sex n (%) 
male  
female  
 
47 (67.0) 
23 (33.0) 
Age (years) 
mean ± SD  
median (min-max)  
 
58.2 ± 10.2 
58.5 (26 – 76) 
BMI (kg/m2) 
mean ± SD 
median (min-max) 
 
26.0 ± 4.0 
25.5 (19 - 35) 
Diagnosis n (%) 
AML, MDS, ALL, CML, MPS   
MM, NHL, CLL, MCL     
 
57 (81.5) 
13 (18.5) 
Conditioning regimens n (%) 
Fludarabine, BCNU, Melphalan (FBM) 
Fludarabine, Thiotepa (FTT) 
Fludarabine, BCNU, Thiotepa (FBTT) 
other1 
 
50 (71.4) 
9 (12.9) 
6 (8.6) 
5 (7.1) 
Remission at transplant n (%) 
early disease (CR1, CP1, RA, RARS)  
advanced disease (all other stages)                  
 
58 (82.9)  
12 (17.1) 
Donor status n (%) 
related        
unrelated                                                                                                                 
 
21 (30.0) 
49 (70.0)
Graft source n (%) 
peripheral blood stem cells 
 
70 (100) 
GVHD prophylaxis 
containing cyclosporine A (CsA)2   
containing certican3                                                               
 
58 (82.9) 
12 (17.1) 
Abbreviations: ALL = acute lymphocytic leukaemia, AML = acute myeloid (myeloblastic) 
leukaemia, CLL = chronic lymphocytic leukaemia, CML = chronic myeloid leukaemia,  
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MCL = mantle cell lymphoma, MDS = myelodysplastic syndrome, MM = multiple mye-
loma, MPS = myeloproliferative syndrome, NHL = Non-Hodgkin‘s lymphoma. 1 Modified 
regimens: fludarabine and melphalan twice, fludarabine once, melphalan and thiotepa, 
fludarabine and thiotepa once and only melphalan once. 2 CsA/Campath 53 (75.7%); CsA 
mono 1 (1.4%), CsA/MMF (Mycophenolate mofetil)/ATG (Anti thymocyte globulin) 2 
(2.9%);CsA/MTX (Methotrexate)/ATG 2 (2.9%). 3 Myfortic/Certican 9 (12.9%), Myfor-
tic/Certican/Campath 2 (2.9%), Certican mono 1 (1.4%) 
 
AOX status in plasma and BMC 
Tab. 6: AOX concentrations in plasma and BMC at baseline and normal 
ranges 
AOX concentrations N Mean ± SD  (min – max) Normal 
range 
Plasma (µmol/L) 
vitamin E 
vitamin C 
ß-carotene 
 
70 
70 
70 
 
31.7 ± 14.9  (12.3 – 91.1) 
42.3 ± 26.2  (3.7 – 101.3) 
0.5 ± 0.5   (0.0 – 2.9) 
 
15 – 40 
30 – 80 
0.2 – 1.0 
BMC (pmol/µg DNA) 
vitamin E 
vitamin C 
ß-carotene 
 
69 
47 
63 
 
27.4 ± 12.5  (3.2 – 61.1) 
4.5 ± 4.5   (0 – 16) 
0.4 ± 0.5   (0 – 2.5) 
 
9.5 – 20.3 
3.9 – 11.1 
0.1 – 0.5 
The mean BMC concentrations of vitamin E, vitamin C and ß-carotene per µg DNA 
were 27.4 ± 12.5 pmol, 4.5 ± 4.5 pmol, and 0.4 ± 0.5 pmol, respectively. Given the 
reference values (Tab. 6), 4/69 (5.8%), 28/47 (59.6%), 6/63 (9.5%) of the patients 
had inadequate BMC concentrations of vitamin E, vitamin C and ß-carotene, respec-
tively.  
 
Baseline AOX concentrations were measured in blood plasma in all patients and BMC 
in 69/70 of the patients due to insufficient cell numbers. Vitamin C and ß-carotene 
concentrations were not detectable in 23/69 and 7/69 of the BMC samples, respec-
tively. The mean plasma concentrations at baseline of vitamin E, vitamin C and ß-
carotene were 31.7 ± 14.9 µmol/L, 42.3 ± 26.2 µmol/L and 0.5 ± 0.5 µmol/L, re-
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spectively. Plasma concentrations of vitamin E, vitamin C and ß-carotene were be-
neath normal range in 3 (4.3%), 26 (37.1%) and 22 (31.4%) of the patients, re-
spectively (Tab. 6). We found significantly high positive correlations between the AOX 
concentrations in blood plasma and BMC for vitamin E (r2 = 0.096, P = 0.009) and ß-
carotene (r2 = 0.823, P <0.001), visualized in Fig. 5, although not for vitamin C. 
 
 
Fig. 5: Relation between the plasma and BMC concentrations of vitamin E and ß-
carotene before conditioning chemotherapy. Simple linear regression was used to assess 
relations. A: n = 69, r2 = 0.096, P = 0.009; B: n = 63, r2 = 0.823, P <0.001 
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2.3.4 Discussion 
Based on the hypothesis that oxidative tissue damage triggered by chemotherapy 
plays an eminent role in the pathogenesis of OM [26,27], we investigated the influ-
ence of the exogenous AOX status, mainly plasma vitamin E before conditioning 
chemotherapy on the incidence and severity of OM. Consistent with the observation 
in an earlier study [100], we observed no significant differences in plasma vitamin E 
status in this study population shortly before the conditioning therapy among pa-
tients suffering from different OM grades after alloHCT. We are the first to analyse 
the plasma and buccal mucosal tissue status of AOX in patients undergoing reduced-
intensity conditioning regimens prior to alloHCT. However, we observed no single 
AOX concentration in plasma or BMC at the actual site of action to demonstrate a 
predictive value for the incidence or severity of OM. However, more than half of the 
patients were deficient in at least one plasma AOX (AOX-inadequacy group) and 
those tended to require longer parenteral nutrition, which is a relevant clinical and 
economic marker for OM treatment [24,23], than patients with all plasma AOX con-
centrations in or above the normal range - a finding that should be considered ex-
ploratory.  
On average, our patients experienced their maximum OM grade on day 12 after the 
start of conditioning, consistent with the time point (on day 13) reported by Bli-
jlevens et al. [22] In accordance with Horsely et al. [101], Blijlevens et al. [22] re-
ported an incidence of ulcerative and severe OM in 64% and 44% of their patients 
receiving high-dose melphalan and BEAM conditioning chemotherapy followed by 
autologous HCT, respectively, whereas we report a markedly less frequent occurrence 
of ulcerative OM (20%). No or mild OM (°0-°I) was the most common diagnosis 
(54%) in our study population, which is perhaps due to the reduced-intensity condi-
tioning regimens used [102]. Fludarabine-based, reduced-intensity conditioning 
regimens have been developed to provide a potentially curative treatment with re-
duced toxicity, specially for older and comorbid patients [64] or for those undergoing 
a second alloHCT [103,104]. Furthermore, Slavin et al. [105] showed that these 
conditioning regimens can reduce treatment-related toxicity including OM. Studies 
showing much higher incidences of ulcerative OM in patients undergoing HCT em-
ployed high-dose conditioning regimens sometimes containing total body irradiation 
[106,25,104]. No difference in maximum OM grades was detected for our different 
conditioning regimens (FBM, FTT and FBTT).  
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This study confirmed that patients with severe OM experienced a significantly higher 
incidence of a clinically-relevant aGVHD grade II-IV [107] and needed significantly 
longer parenteral nutrition [23] than patients with no or mild OM.  
Consistent with our observation of overall adequate plasma vitamin E status (except 
in 4.3% of our patients), earlier studies reported similar circulating vitamin E con-
centrations prior to conditioning chemotherapy [108,100,109,110] and in a large 
group of patients with haematological malignancies [111], respectively. At admis-
sion, mean plasma vitamin C and ß-carotene concentrations were within normal 
ranges, in accordance with other studies [109,112,110]. However, around one third 
of our patients presented reduced plasma concentrations of vitamin C and ß-
carotene, respectively.  
Up to now, very few studies have investigated AOX status in BMC in the general 
population [113,114], let alone in patients undergoing alloHCT. Using the reference 
values provided by our analysing laboratory, few patients (6%) showed reduced vi-
tamin E status in BMC. Inadequate concentrations of vitamin C and ß-carotene were 
found in 60% and 10% of the evaluable samples, respectively. The high incidence of 
low vitamin C concentrations in BMC may be due to a methodical error in the sample 
processing. In line with others [115,113,30], we found significantly high positive cor-
relations between the AOX concentrations in blood plasma and BMC for vitamin E 
and ß-carotene. 
A limitation of this study relates to the very low incidence of inadequate plasma vi-
tamin E concentrations, while detecting a difference in patients with different OM 
grades was impeded. A further limitation is that the incidence of ulcerative OM was 
lower than expected. Reports on plasma vitamin E [116,109,117], ß-carotene 
[116,109] and overall AOX capacity [112,117] courses after high-dose chemotherapy 
followed by HCT showed significant decreases even when the patients received the 
recommended dietary allowances of vitamin E by total parenteral nutrition 
[109,117]. This implies that data on AOX status over the brief period after chemo-
therapy and before HCT may well be more reliable in providing further evidence of 
the role of a good AOX supply for OM prophylaxis. 
A recent review by Block et al. [118] provided evidence that AOX supplementation 
during chemotherapy holds potential for reducing dose-limiting toxicities 
[119,120,98], however several studies reported that AOX might protect tumour cells 
and reduce treatment efficiency [121,122]. From this follows that well-designed ran-
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domised trials investigating the cytoprotective properties of AOX in the cancer ther-
apy-induced pathogenesis of OM should therefore administer AOX in a safe way to 
avoid impairing treatment efficacy. A safe and efficient way to improve the cellular 
supply in the buccal mucosa is the topical application of AOX via a rinsing solution 
[28,122,98]. 
In conclusion, no single AOX, either in plasma or BMC (vitamin E, vitamin C and ß-
carotene), revealed predictive value for the incidence or severity of OM. Patients with 
an overall good plasma AOX status tended to require less parenteral nutrition, a 
common clinical marker for OM. We hypothesize that an intact antioxidative network 
may be more relevant than any one AOX to reduce the OM risk. Future studies 
should consider both the exogenous- and endogenous AOX systems. 
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2.4 Course of serum 25-hydroxyvitamin D3 status and its 
influencing factors in adults undergoing allogeneic 
haematopoietic cell transplantation 
Course of vitam in D status 
2.4.1 Introduction 
Vitamin D has biological effects far beyond its hormonal activity in maintaining cal-
cium homeostasis [123], including immunomodulatory activity [124,125], regulating 
angiogenesis [126] and cellular differentiation [127], proliferation [128], and apop-
tosis [129] of both normal and malignant cells. Current studies suggest that hypovi-
taminosis D at diagnosis may be associated with poorer prognosis in a wide range of 
solid malignancies [31-34]. A study by Shanafelt el al. [35] recently provided the 
first direct evidence that low serum 25-hydroxyvitamin D3 [25(OH)D3] concentrations 
may be associated with poorer overall survival (OS) in haematological malignancies. 
Moreover, osteoporosis, a common, relevant complication in recipients of alloHCT, is 
one of the factors linked to immunosuppressive therapy and reduced serum 
25(OH)D3 concentrations [130,38,131]. Furthermore, vitamin D analogs alleviate 
graft-versus-host disease (GVHD) in cell cultures [36] and rats [132,133]. Thus, cor-
recting vitamin D deficiency and maintaining adequate vitamin D status before and 
after alloHCT may improve short- and long-term outcome parameters.  
Two studies with small numbers of patients have thus far assessed vitamin D status, 
revealing that vitamin D deficiency is highly prevalent in adult patients undergoing 
alloHCT [37,38], while one study showed 25(OH)D3 concentrations within the lower 
normal range [134]. 
So far, only potential influencing factors on post-transplant vitamin D status at a 
mean time since HCT of 4.4 months and 4.2 years were investigated in paediatric 
patients [39] and paediatric and adult patients [135], respectively. To deepen under-
standing and develop future preventive and interventional approaches, the main ob-
jective of this study was to first determine those factors exerting significant influence 
on serum 25(OH)D3 status before conditioning chemotherapy followed by alloHCT in 
adult patients. In addition, we are the first to describe the impact of influencing fac-
tors on the course of serum 25(OH)D3 in the early post-transplant period until day 
+100. 
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2.4.2 Patients and methods 
Study population  
Adult patients with haematological malignancies admitted to our institution (the Uni-
versity Medical Centre Freiburg) between 2008 and 2010 for an alloHCT were eligible 
to enter this prospective survey. The study protocol was approved by our local Ethics 
Committee, and all patients provided informed consent.  
Study design and data collection 
Data were gathered at three time points: admission (baseline), day +30, and day 
+100 after alloHCT. At each time point, we assessed serum 25(OH)D3 concentrations 
and if appropriate, factors potentially influencing serum 25(OH)D3. All further (includ-
ing medical) data were collected from hospital records. Nutritional interventions fol-
lowed standard institutional clinical practice, including parenteral nutrition, dietary 
counselling, and prescription of a multivitamin supplement (vitamin D free) until day 
+100. Serum samples were collected routinely in the early morning at each time 
point. Our Department of Clinical Chemistry (certified according to ISO 9001) used 
an electrochemiluminescence immunoassay with specificity only to 25(OH)D3. Hy-
povitaminosis D was defined as a serum 25(OH)D3 concentration <30 ng/ml (75 
nmol/L) and the lower limit of analytical determination was 4 ng/ml.  
Factors potentially influencing serum 25(OH)D3 
Outdoor activities: As the major source of vitamin D in humans is sunlight-induced 
cutaneous vitamin D3 synthesis, we assessed at baseline and day +100 the patients’ 
sun exposure habits and time per day usually spent outdoors during the last month. 
Mean daily outdoor activity was graded as: outdoors <1 h, low, 1-3 h moderate, and 
>3 h high.  
Season: Considering the seasonal fluctuation of UV-B irradiation, we divided the 
year in one period from April through September (the “increasing” season), when 
sun exposure at 48° north latitude suffices for cutaneous vitamin D synthesis [136] 
and a period from October through March (the “decreasing” season), when UV-B en-
ergy is low, leading to a continuous drop in serum 25(OH)D3.  
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Dietary and supplementary vitamin D intake: We interviewed the patients at 
baseline and day +100 about their dietary habits in the last month using a short, 
semiquantitative food-frequency questionnaire including all food groups containing 
vitamin D3 in noteworthy concentrations, i.e. fish, eggs and dairy products. In this 
dietary interview, patients were asked about their use of vitamin D3 supplements and 
frequency of intake. We categorized the mean vitamin D3 content of these foods, 
usual serving sizes, and frequency of consumption as low, medium, or high due to 
their potential impact on serum 25(OH)D3: fish (≤1, 2-3, ≥4 times monthly), eggs 
(≤1, 2-3, ≥4 times weekly), dairy products (≤3, 4-6, ≥7 times weekly). Although 
mushrooms are a good source of vitamin D2, we disregarded their consumption be-
cause our analytical method was not sensitive to serum 25(OH)D2.  
Parenteral nutrition: As parenteral nutrition (when supplemented by lipid-soluble 
vitamins) is an important source of vitamin D during the very early post-transplant 
period during hospitalization, we recorded the duration of parenteral nutrition and 
administration of lipid-soluble vitamins (200 IU of vitamin D3/d).  
Body fat mass: To investigate the influence of body fat on serum 25(OH)D3, we 
used the fat mass in percent of body weight measured by bioelectrical impedance 
analysis (BIA). The BIA instrument used was a multifrequency device (Body Scout 
instrument, Nutritional Management Tool software version 2.0, Fresenius Medical 
Care, Germany) and conditions were standardized when measuring [63]. 
We also assessed age, gender, body mass index (BMI) and the Karnofsky perform-
ance status (KPS). We documented the maximum grade of acute graft-versus-host 
disease (aGVHD) (°0-°IV) as a factor potentially influencing  the serum 25(OH)D3 
course according the criteria of Przepiorka et al. [137]. 
Statistical analysis 
We used IBM SPSS 19 for statistical analysis (IBM, NY, USA). For descriptive data 
analyzes, all values are presented as means ± SDs and when useful (min - max). 
Paired t-tests were used to analyze differences over time in continuous variables. 
Two sample t-tests were employed for group comparisons. To examine the impact of 
potentially influencing factors for serum 25(OH)D3 at transplantation, we used linear 
regression models with serum 25(OH)D3 concentrations as the dependent variable. 
First, univariate models were employed for a preliminary assessment of single fac-
tors. Then, a multivariate model was constructed with those variables showing a uni-
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variate P <0.1. Results of the linear regression models are presented as parameter 
estimates for the regression coefficients with accompanying 2sided 95% confidence 
intervals (CI). For continuous independent variables (e.g. age, BMI, fat mass), the 
regression coefficient represents the increase in serum 25(OH)D3 concentration for a 
one-unit increase in the respective continuous variable. For binary independent vari-
ables (all other variables), the regression coefficient describes the difference in se-
rum 25(OH)D3 concentrations between two groups. 
2.4.3 Results 
Patient and transplant characteristics 
Baseline and transplant characteristics of the 102 Caucasian adults are summarized 
in Tab. 7. The 37% female and 63% male patients with a mean age of 56 ± 11 years 
(range: 22-76) had a mean BMI of 25.9 ± 4.1 kg/m2. Diagnoses were acute leuke-
mias or other myeloid malignancies (76.5% AML, ALL, CML, MDS, MPS) and lym-
phoid malignancies excluding ALL (23.5%; NHL, MM, CLL, MCL). Peripheral blood 
stem cells were the graft in all transplantations. Seventy-three patients (71.6%) had 
advanced or active disease; 29 (28.4%) patients with early disease were trans-
planted.  
By day +30, three patients had dropped out, as did another 11 patients by day +100 
due to death or poor general condition. We had no data from day +30 from six pa-
tients, mainly because of early discharge. Mean time between baseline and alloHCT 
was 11.6 ± 6.7 days, whereas day +30 was 28.6 ± 2.9 days, and day +100 was 
99.4 ± 6.5 days after alloHCT, respectively.  
 
Tab. 7: Patient, transplant characteristics and baseline serum 25(OH)D3  
(n = 102) 
Gender n (%) 
male  
female  
 
64 (63.0) 
38 (37.0) 
Age (years) 
mean ± SD  
min-max 
 
56 ± 11 
22-76 
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BMI (kg/m2) 
mean ± SD 
 
25.9 ± 4.1 
Diagnosis n (%) 
AML, MDS, ALL, CML, MPS   
MM, NHL, CLL, MCL     
 
78 (76.5) 
24 (23.5) 
Conditioning regimens n (%) 
reduced-intensity (fludarabine-based) 
[64]  
myeloablative  
 
93 (91.2) 
9 (8.8) 
Remission at transplant n (%) 
early disease (CR1, CP1, RA, RARS)  
advanced disease (all other stages)                                        
 
29 (28.4)  
73 (71.6)
Donor status n (%) 
related        
unrelated                                                                                                                 
 
24 (23.5) 
78 (76.5)
Graft source n (%) 
peripheral blood stem cells 
 
102 (100%) 
GVHD prophylaxis 
containing cyclosporine A 
containing certican                                                              
 
89 (87.2) 
13 (12.8)
Serum 25(OH)D3 (ng/ml) n (%) 
mean ± SD  
min-max 
sufficient  (≥30 ng/ml)  
insufficient  (10-30 ng/ml) 
deficient  (≤10 ng/ml) 
 
16.4 ± 8.9  
4-47 
11 (10.8) 
67 (65.7) 
24 (23.5) 
Abbreviations: ALL = acute lymphocytic leukemia, AML = acute myeloid leukemia, BMI = 
body mass index, CLL = chronic lymphocytic leukemia, CML = chronic myeloid leukemia, 
CR1 = complete remission, CP1 = chronic phase, MCL = mantle cell lymphoma, MDS = 
myelodysplastic syndrome, MM = multiple myeloma, MPS = myeloproliferative syn-
drome, NHL = Non-Hodgkin’s lymphoma, RA = refractory anemia, RARS = refractory 
anemia with ringsideroblasts, SD = standard deviation.  
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Serum 25(OH)D3 concentrations  
The mean serum 25(OH)D3 concentration was 16.4 ± 8.9 ng/ml (range: 4-47) at 
admission, thus most our study cohort 90/102 (89.2%) had a status under the nor-
mal range (30-70 ng/ml), whereby 23.5% presented extremely low concentrations 
(<10 ng/ml) (Tab. 7). When evaluating the serum 25(OH)D3 course during the study 
period, we only considered the 67 patients from whom we had complete data records 
of 25(OH)D3. [N = 67 originates from: 14 drop-outs during the study, 6 examples of 
missing serum samples due to early hospital discharge, and 16 insufficient samples. 
One patient's sample was insufficient twice (on days +30 and +100). As a result, we 
had complete 25(OH)D3 data sets of 67 patients available in total.] We found a slight 
and constant, but statistically not significant overall decrease in serum 25(OH)D3 by 
8.4% from baseline (16.2 ± 8.1 ng/ml) until day +100 post alloHCT (14.9 ± 7.5 
ng/ml). Serum 25(OH)D3 concentration at day +30 was 15.5 ± 8.7 ng/ml.  
Exo- and endogenous vitamin D supply  
The relevance of the two major vitamin D sources, namely sunlight-induced endoge-
nous vitamin D3 synthesis and exogenous oral vitamin D intake at baseline and day 
+100 is illustrated in Fig. 6 and Fig. 7, respectively. We had access to and evaluated 
the complete baseline and day +100 lifestyle data from 73 of the patients. Fig. 6 
shows the percentage of patients engaging in a low, moderate or high degree of daily 
outdoor activities. At admission, 23/73 (32%) of the patients reported a high aver-
age time spent outdoors each day, while only 7% did so 100 days after alloHCT due 
to guidelines recommending the avoidance of direct sunlight exposure after alloHCT. 
Fig. 7 shows the percentage of patients consuming the three vitamin D3-rich food 
categories at baseline and day +100 at a frequency with a potentially low, medium, 
or high impact on vitamin D supply. A high intake (≥7 times weekly) of dairy prod-
ucts remained constant in approximately 70% of the patients before and 100 days 
after alloHCT. High fish consumption (≥4 times monthly) was reported by 36% and 
42% at baseline and day +100, respectively. High egg consumption (≥4 times 
weekly) was rare during the study. Eating habits in terms of vitamin D-rich foods 100 
days after transplantation did not change noticeably from baseline habits. Eight 
patients took vitamin D3 supplements daily at baseline [a median amount of 200 IU 
(range: 100-500)], whereas only one patient did so on day +100. 
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Fig. 6: Percentage of patients reporting low (<1 h), medium (1-3 h), or high (>3 h) daily 
outdoor activities in the month prior to baseline, and on day +100. N = 73, where out-
door activities data from baseline and day +100 were complete. 
 
 
Fig. 7: Percentage of patients with a potentially low, medium, or high impact on serum 
25(OH)D3 due to their consumption of vitamin D-rich foods (fish, eggs, dairy products) 
and due to their daily intake of vitamin D supplements. Low, medium, or high impact 
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groups were defined as follows: fish (≤1, 2-3, ≥4 times monthly), eggs (≤1, 2-3, ≥4 
times weekly) and dairy products (≤3, 4-6, ≥7 times weekly). N = 73, where nutrition 
data were complete from baseline and day +100. 
 
Impact of influencing factors on baseline 25(OH)D3 status 
In univariate analysis, only female sex and higher body fat mass (%) had a signifi-
cant impact on reduced 25(OH)D3 concentrations (Tab. 8). In contrast, age, BMI, 
KPS, days between primary diagnosis and HCT, number of chemotherapy cycles be-
fore HCT, season, daily outdoor activities, use of vitamin D supplements, consump-
tion of fish, eggs and dairy products were not associated with baseline vitamin D 
status. A multivariate regression model was constructed with those variables show-
ing a relationship (P <0.1) to baseline vitamin D status. Our results are presented in 
Tab. 8. After multivariable adjustment, only fat mass (%) was identified as an inde-
pendent influencing factor of baseline 25(OH)D3 concentrations (parameter estimate 
-0.27;  95% CI: -0.47, -0.08; P = 0.007). After multivariate adjustment, the gender 
association disappeared. Female patients had a significantly higher percentage of 
body fat mass than men (38.2 ± 9.3% vs. 29.6 ± 9.3%, P <0.0001), suggesting 
that the gender difference in serum 25(OH)D3 in the univariate analysis is based on 
the women’s higher body fat mass. 
 
Tab. 8: Results of regression analysis investigating potential influencing 
factors of baseline serum 25(OH)D3 in patients undergoing alloHCT 
Influencing factors 
of baseline serum 
25(OH)D3 
Unit 
Parameter estimate 
(95% CI) 1 
P value 
Univariate analysis (n = 102) 
Age years 0.07 (-0.09, 0.23) 0.41 
Gender male vs female -3.50 (-7.10, 0) 0.05 
BMI kg/m² -0.10 (-0.53, 0.33) 0.65 
Time between primary 
diagnosis and HCT 
days 0.04 (-0.002, 0.003) 0.70 
Chemotherapy cycles 
before HCT2 
numbers -0.10 (-0.90, 0.28) 0.30 
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Remission at HCT 
early vs advanced 
disease 
0.19 (-0.17, 7.46) 0.06 
Body fat mass  % (n = 100) 3 -0.29 (-0.47, -0.11) 0.001 
KPS ≤80 vs >80 2.68 (-1.06, 6.42) 0.16 
Season 
decrease vs in-
crease 
-1.31 (-4.81, 2.19) 0.46 
Outdoor activities low vs high (n = 50) 2.76 (-2.89, 8.41) 0.33 
Food consumption 
        Fish low vs high (n = 90) 0 (-3.91, 3.91) 1.00 
        Eggs low vs high (n = 78) 3.59 (-5.48, 12.66) 0.43 
        Dairy products low vs high (n = 94) 1.64 (-2.52, 5.80) 0.44 
Vitamin D supple-
ments 
daily use vs no use  2.96 (-3.60, 9.52) 0.37 
Multivariate analysis (n = 100)3 
Gender male vs female -0.03 (-4.37, 3.43) 0.81 
Fat mass (%) % -0.28 (-0.46, -0.07) 0.009 
Remission at HCT early vs advanced 0.15 (-0.93, 6.63) 0.14 
Abbreviations: BMI = body mass index, CI = confidence intervals, HCT = haematopoietic 
cell transplantation, KPS = Karnofsky performance status. 1 Parameter estimates repre-
sent the change in baseline serum 25(OH)D3 concentrations for a one-unit increase of a 
continuous factor (e.g. age), or the difference in baseline serum 25(OH)D3 concentra-
tions when comparing two levels of a binary factor (e.g. gender). 2 Excluding extra condi-
tioning. 3 n = 100 instead of 102, because body fat mass via bioelectrical impedance 
analysis was only doable in 100 patients at baseline.  
 
Factors potentially influencing the course of 25(OH)D3 
Due to the tremendous loss of body fat mass in 17% of the cohort (baseline: 26.2 ± 
9.8 kg, day +100: 21.8 ± 8.9 kg; P <0.0001) during the early post-transplant pe-
riod, we investigated the possible effect of vitamin D mobilization in body deposits, 
mainly in adipose tissue, by comparing patients showing a high to those presenting a 
low decrease or even increase in fat mass during the study period. In the end, we 
observed no differences in the amount of change in serum 25(OH)D3 concentrations 
in either group. 
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We identified no significant difference in serum 25(OH)D3 changes when comparing a 
subgroup of patients not receiving lipid-soluble vitamins between baseline and day 
+30 (n = 42) to those receiving parenteral nutrition (including 200 IU vitamin D3) on 
≥20% of the days [n = 23; 35% (range: 21-84)].  
Corticosteroid-treated, clinically-relevant aGVHD (°II-°IV) developed in 35 (43%) of 
82 patients with all relevant data. One hundred days after alloHCT, a trend (P = 
0.066) toward lower serum 25(OH)D3 concentrations was found in patients develop-
ing clinically-relevant aGVHD (°II-°IV) with a decreased by of 23.1% (n = 24; serum 
25(OH)D3 baseline: 17.3 ± 8.3 ng/ml, day +100: 13.3 ± 7.8 ng/ml). In contrast, 
serum 25(OH)D3 remained constant in patients with no or mild aGVHD (°0-°I) (n = 
58; serum 25(OH)D3 baseline: 15.6 ± 8.4 ng/ml, day +100: 15.3 ± 7.7 ng/ml). 
2.4.4 Discussion 
Very striking was our study cohort’s overall low 25(OH)D3 status before conditioning 
chemotherapy started, whereas a quarter showed extremely low serum concentra-
tions (under 10 ng/ml), revealing a much higher prevalence of extreme low 
25(OH)D3 concentrations than the 16% reported in a representative sample of the 
German adult population [41]. Apart from one report in which median serum 
25(OH)D3 concentrations fell within the lower normal range [134], the prevalence of 
low 25(OH)D3 status before alloHCT in this study is similar to results reported by 
Schulte et al. [38] and Kreutz et al. [37]. As those studies reported significant drops 
in serum 25(OHD)D3 at the time point of engraftment [37] or on day +28 [38], we 
also noted a slight trend towards a continuous fall until day +100. Interestingly, Ro-
bien et al. [135] found in long-term HCT survivors 4.2 years after transplantation 
serum 25(OH)D concentrations above 30 ng/ml, whereby the majority of participants 
reported regular use of vitamin D supplements. 
We are the first to prospectively investigate the impact of well-known influencing 
factors including age, gender, body fat mass, oral vitamin D intake, plus season and 
outdoor activities, as surrogates of UV-B irradiation and endogenous vitamin D syn-
thesis on baseline serum vitamin D status in adults undergoing alloHCT. Surprisingly, 
we observed no seasonal variation in baseline serum 25(OH)D, which is the strong-
est influencing factor reported consistently in healthy subjects [41,138,139]. Like-
wise, a recent study in paediatric HCT demonstrated that the testing time of year 
was not a risk factor for vitamin D deficiency, most likely due to little outdoor activity 
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and the frequent use of sunscreen [39]. We assume that this lack in our study can 
be partly explained by our high number of patients with advanced disease at admis-
sion, which is often associated with prolonged disease history and hospitalization. 
The season after discharge till day +100 had no influence on serum 25(OH)D3 
changes during that period either, most probably due for the most part to the medi-
cal advice to avoid unprotected sun exposure. Univariate analysis revealed that no 
one food, nor the use of vitamin D supplements had any noticeable influence on 
vitamin D status in this cohort.  
Obesity, thus increased body fat stores, have consistently been found to be associ-
ated with significantly lower serum 25(OH)D concentrations [140,141,135,142], 
probably because of augmented deposits in fat stores [142]. Baseline body fat mass 
was the only independent predictor of vitamin D status in our study cohort. To ex-
pand previous reports [140,142], we investigated the impact of increased fat mass 
breakdown with the potential release of stored vitamin D on vitamin D status, and 
failed to observe a positive effect of losses in body fat mass on serum 25(OH)D3 dur-
ing the study period. Changes in serum 25(OH)D3 seemed to be independent of body 
composition changes during the first 100 days after alloHCT.  
The trend toward a decrease in serum 25(OH)D3 concentrations during the first 100 
days after alloHCT in patients with clinically-relevant and corticosteroid-treated 
aGVHD (°II-°IV) observed in our study resembles the results reported by Kreutz et 
al. [37], who showed this effect in patients with severe aGVHD (°III-°IV). It is be-
lieved that this inverse association between aGVHD and serum vitamin D is due to 
the intestines’ impaired capacity to absorb lipid-soluble vitamins [37]. Clinically-
relevant aGVHD (≥°II) is treated with corticosteroids, potential confounders due to 
their known negative effects on vitamin D metabolism [143,144]. Future studies 
should assess GVHD-associated gastrointestinal disorders (e.g. diarrhea) to be able 
to discern effects of corticosteroids from those of malabsorption on vitamin D status.  
Patients receiving 200 IU of vitamin D3 via a daily infusion of lipid-soluble vitamins 
on at least 20% of the days spent on transplantation ward did not reveal a different 
course in serum 25(OH)D3 than patients without parenteral nutrition, never mind an 
improvement in serum 25(OH)D3. Strengthened by results from Schulte et al. [38] 
[who reported that serum 25(OH)D concentrations decreased during the first 4 
weeks after alloHCT although all patients received vitamin D supplementation in their 
parenteral nutrition (200 IU/d)] and in accordance with Robien et al. [135], we be-
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lieve that the current recommended daily allowance for adults in Germany is insuffi-
cient to meet these patients’ specific micronutrient requirement in this extreme 
situation. But what the appropriate vitamin D supplementation for these patients 
could be, as their individual needs differ considerably due to divergent clinical condi-
tions and medications, still remains unknown. 
Hypovitaminosis D is a major risk factor for bone loss leading to osteoporosis via 
secondary hyperparathyroidism [145]. In addition to widely-used corticosteroids and 
cyclosporine A in post-alloHCT believed to be responsible for bone loss [146], hypovi-
taminosis D may play an important role in the dramatically increased bone resorption 
before alloHCT and in the poor recovery of bone mineral density one year after 
alloHCT [38]. A recent health implication of vitamin D is the potential reduction in 
adverse effects of GVHD while maintaining the graft vs tumour effect. Based on 
vitamin D’s immunomodulatory properties, Rosenblatt et al. [36] published in vitro 
data showing that vitamin D exposure inhibits differentiation of dendritic cells (DCs) 
resulting in immature DCs exerting a tolerating influence on allo-reactive T-cell popu-
lations. 
A study limitation is the semi-quantitative method we used instead of a validated 
dietary assessment, which would have enabled us to estimate individual vitamin D 
intakes.  Further limitations for this analysis are associated with the great difficulty 
to accurately assess sunlight exposure. We thus documented the season and outdoor 
activities as approximate measures of sunlight. Furthermore, issues of statistical 
power should certainly be considered when inspecting the results of our analyses. 
When investigating the impact on 25(OH)D3 concentrations of factors with a strongly 
unbalanced distribution [Table 2, e.g. daily use of vitamin D supplements (n = 8) vs 
no use (n = 94)], results are based on small group sizes, leading to large confidence 
intervals.  
In conclusion, hypovitaminosis D was a frequent condition in patients undergoing 
alloHCT in this monocentric study within our specific geographical region. Surpris-
ingly, the most important influencing factors according to the current literature, such 
as season and vitamin D-rich foods, seemed to have an only minor impact on base-
line vitamin D status. As expected, 25(OH)D3 status remained low in the early post-
transplant period, showing a trend towards further deterioration, especially in pa-
tients with corticosteroid-treated aGVHD. In addition, reduced outdoor activity com-
bined with the medical advice to avoid unprotected sun exposure, and an inadequate 
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supply via nutrition and vitamin D supplements, mean that without appropriate 
measures e.g. sufficient vitamin D supplementation, achieving higher serum 
25(OH)D3 concentrations is virtually impossible. Moreover, our results provide a clear 
rationale for the use of at least vitamin D containing multivitamin preparations in the 
case of standard multivitamin prescriptions and for the monitoring of vitamin D 
status at regular intervals from the date of diagnosis. 
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2.5 Bioavailability of vitamin D2 from UV-B-irradiated button 
mushrooms in healthy adults deficient in serum 25-
hydroxyvitamin D: a randomized controlled trial 
Vitam in D2-enhanced mushrooms 
2.5.1 Introduction 
Low vitamin D status, defined as a serum 25-hydroxyvitamin D [25(OH)D] concen-
tration <50 nmol/L [147,148], is a public health issue prevalent worldwide [40-43], 
particularly in regions with a big seasonal shift in solar altitude, as the major source 
of vitamin D for humans is sunlight-induced cutaneous synthesis [44,45]. Other cri-
teria, like dark skin [149,150], old age [140], and immobility [151] further reduce 
the endogenous vitamin D synthesis. Moreover, few foods contain vitamin D in note-
worthy concentrations; those that do are fish-liver oils, fatty fish, and egg yolk. Fur-
thermore, there is a wide variety of foods fortified with vitamin D across the world 
[152], e.g. dairy products, bread, and recently, orange juice [153-155].  
Naturally, the vitamin D2 content of cultivated mushrooms is almost nil [<0.1 µg/100 
g fresh weight], yet they are very rich in ergosterol [46,47]. Ergosterol is the princi-
pal sterol in fungi, and several studies have reported that mushrooms can be greatly 
enhanced with vitamin D2 by ultraviolet (UV) irradiation, resembling the cutaneous 
synthesis of vitamin D3 in humans [48,156]. The conversion rate of ergosterol to vi-
tamin D2 under UV irradiation depends on the UV spectrum (UV-B or -C), irradiation 
dose, moisture content, and the mushrooms’ orientation toward the UV source 
[46,157,158].  
Outila et al. (1999) were the first to demonstrate that vitamin D2 was well absorbed 
from lyophilized and homogenized mushrooms in humans. Jasinghe et al. (2005, 
2006) were the first to publish in vivo studies on the bioavailability of vitamin D2 
from UV-irradiated mushrooms, showing as others [159] that vitamin D2 from vita-
min D2-enhanced mushrooms is well absorbed and metabolized in rodents, and that 
it improves bone mineralization.  
Recently the case history of a patient with vitamin D deficiency and secondary hy-
perparathyroidism was published, who refused to take supplements, but self-treated 
his deficiency by consuming mushrooms daily, which he had exposed to UV-B irradia-
tion [160].  
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To the best of our knowledge, this is the first report on the bioavailability of vitamin 
D2 from UV-treated mushrooms in humans. Hence the primary objective of this ran-
domized controlled trial was to demonstrate the possibility of improving the 25(OH)D 
status with this natural food source in terms of a higher serum 25(OH)D concentra-
tion in young adults with low 25(OH)D status 4 weeks after a weekly vitamin D2 dose 
of 28 000 IU (700 µg) compared to placebo. A secondary objective was to compare 
the bioavailability of vitamin D2 from UV-B treated mushrooms with a vitamin D2 
supplement. 
2.5.2 Subjects and methods 
Subjects 
Subjects were recruited from employees of the University Medical Center Freiburg by 
advertising. The study protocol was approved by our Ethics Commission. Exclusion 
criteria included kidney stones, pregnancy, anticonvulsant or steroid therapy in any 
form, frequenting a tanning salon, or residence in the mountains or southern coun-
tries right before or during the study. The subjects were not allowed to take vitamin 
D supplements or fish liver oils, and were asked to eat fish no more than once a 
week. 
Caucasian adults in good general health, younger than 45 years with a body mass 
index (BMI) between 18.5-26 kg/m², and not fulfilling any exclusion criterion were 
eligible to provide blood specimens for further testing after having signed a written 
consent form. Out of 49 female and male volunteers we randomized 27 subjects with 
low serum vitamin D (25(OH)D ≤50 nmol/L) and normal serum calcium concentra-
tions (2.2-2.7 mmol/L) to enter the study. 
Study design 
This study was a 5-week, prospective, randomized, 3-arm, single-blind, placebo-
controlled trial to investigate the bioavailability of vitamin D2 from UV-B-irradiated 
button mushrooms and vitamin D2 supplement, respectively. 
The four first weekly visits (weeks 0, 1, 2, 3) constituted the interventional part of 
the study and the two last visits (weeks 4, 5) served as follow-up. The primary ob-
jective and further endpoints were analyzed till week 4, because that is when we ex-
pected the strongest interventional effect. At the initial, baseline visit (week 0), 
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weight and height were documented. At each subsequent weekly visit at the same 
time of day blood was drawn. The study was performed during the winter from late 
January till early March 2010, when a) a low vitamin D status in healthy subjects is 
most likely, and b) solar UV-B radiation is minimal to avoid the confounding effect of 
cutaneous vitamin D3 synthesis on our intake-response evaluation.  
Our 27 blinded subjects were randomly assigned into 3 equal groups [a) mushroom, 
b) supplement, c) placebo] using a computer-generated sequence to receive 4 times 
at weekly intervals either a) 28 000 IU vitamin D2 via 365 g of the experimental soup 
containing the UV-B-irradiated mushrooms (vitamin D2 content of 191.8 µg/100 g) 
and placebo, or b) 60 IU vitamin D2 via a conventional mushroom soup and 28 000 
IU vitamin D2 via a supplement (equivalent of 70 drops), or c) 60 IU vitamin D2 by a 
conventional mushroom soup and placebo, respectively. The liquid supplement used 
(Stérogyl, Desma Pharma, Paris, France) provided 400 IU per drop (verified as 393 
IU per drop by SGS Institut Fresenius, Berlin, Germany), consisted of an ethanol 
formulation of vitamin D2 and was dissolved in orange juice. The placebo consisted of 
pure orange juice. The supplement or placebo was served shortly before the soup. 
Soup intake was supervised and remains of the soup were absorbed by bread and 
eaten.  
Blood sample analysis 
The blood samples were stored for coagulation about 30-60 min in the dark at room 
temperature previous to centrifugation (2.000 rpm for 7 min). The serum samples 
were frozen at -78 °C until weekly analysis of all samples of one blood drawing by 
the laboratory MVZ Clotten (Freiburg, Germany). Serum 25(OH)D2 and serum 
25(OH)D3 were measured combined as 25(OH)D by a radioimmunoassay (RIA) pur-
chased from DiaSorin Inc. (Stillwater, MN, USA). The quality and accuracy of the se-
rum 25(OH)D analysis were monitored by interlaboratory tests evaluated by 
INSTANT e.V. (Duesseldorf, Germany). The detection limit for the RIA assay was 10 
nmol/L, inter- and intraassay coefficients of variation for 25(OH)D were 11.1% and 
10.1%. The cross-reactivity of each compound, normalized to 25(OH)D3 and above 
1% is specified by the manufacturer as 104%, 40% and 17% with 25(OH)D2, 
1,25OH2D2, and 1,25OH2D3, respectively. Serum intact parathyroid hormone (iPTH) 
was measured by non-competitive immunoassay on the Roche Modular Analytics 
E170. Serum calcium was measured using a photometric color test with Olympus 
calcium Arsenazo III OSR60117. The reference ranges were 50-175 nmol/L,        
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1.2-4.5 pmol/L and 2.2-2.7 mmol/l, for 25(OH)D, iPTH and serum calcium, respec-
tively. Serum 25(OH)D and calcium were measured weekly, serum iPTH was meas-
ured twice at week 0 and week 4. 
Irradiation of mushrooms 
We used fresh brown button mushrooms (Agaricus bisporus) provided by a local 
mushroom producer (Schlossbergpilze, Freiburg, Germany) with a moisture content 
of 91.4%, determined by the vacuum oven method. To produce vitamin D2-enhanced 
mushrooms, they were placed completely separated from each other on a 2 cm 
meshed grid, and each side was irradiated simultaneously with UV-B (306 nm) at an 
irradiation dose of 1.5 J/cm2 after 25 min at ambient temperature (22 °C). The cus-
tom-made UV unit was equipped with 8 UV-B lamps 176 cm in length (UV21, 
Waldmann, Villingen-Schwenningen, Germany). The total irradiation area was     
0.72 m2 with a homogeneous intensity of UV-B. The radiation dose was measured by 
a radiometer (UV34, PCE Group, Meschede, Germany).  
Soup preparation and analytic method 
Directly after irradiation, the mushrooms were diced and used in a puréed mushroom 
soup. All the experimental and conventional mushroom soups needed for the study 
were portioned out and stored in a freezer at -20 °C. Soup ingredients were water, 
button mushrooms, soy cream, flour, olive oil and spices [4.2% fat, 0.8% protein, 
2.9% carbohydrates (weight/weight)]. Soup and mushroom samples were shipped 
on dry ice to SGS Institut Fresenius (Berlin, Germany) for vitamin D2 analysis. The 
assay is based on semipreparative HPLC purification followed by analytical reversed-
phase HPLC. Preliminary tests (data not shown) showed that the experimental soup’s 
vitamin D2 remained very stable during cooking, freezing, defrosting, and reboiling. 
The mushroom soups were well tolerated. 
Sample size calculation and statistics 
The study was designed to detect a difference of 20 nmol/L in 25(OH)D serum con-
centrations between the mushroom and placebo groups with a power of 80% with a 
one-sided t-test at a significance level of 5%. The assumed standard deviations (SD) 
were 13.0 in the placebo and 14.7 in the mushroom groups, derived from previous 
investigations. The resulting sample size was 7 per group. The study was analyzed 
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using SPSS version 16.0 (SPSS Inc, Chicago, IL, USA) and SAS version 9.2 (SAS In-
stitute Inc, Cary, NC, USA). 
For descriptive data analyses, values are presented as means ± SDs. Group com-
parisons were made using two sample t-tests and one-way ANOVA with post hoc 
Tukey tests. P-values will be provided for the comparisons of secondary objectives 
and should be regarded as exploratory. Results with P <0.05 will be denoted as sig-
nificant. The development of 25(OH)D concentrations during the study was investi-
gated using a random effects model (SAS proc mixed) with 25(OH)D as dependent 
variable, different time slope parameters for each treatment group (i.e. 
time*treatment interaction) and subject specified as a random effect. Treatment dif-
ferences during the study can thus be investigated by testing the differences in time 
slopes. Results will be given in terms of estimates for regression slope parameters 
which represent the 25(OH)D increase per week in each group and their accompany-
ing 95% confidence intervals. 
2.5.3 Results 
Baseline characteristics of subjects 
Of the 27 subjects recruited for the study, one from the mushroom group dropped 
out because of pregnancy before the first visit, while 26 completed the interventional 
phase and were used for the further evaluation. One subject had to miss the last fol-
low-up blood withdrawal (week 5). Characteristics of the study population are sum-
marized in Tab. 9. Mean age and BMI of the subjects were 30.8 ± 5.8 y and 22.1 ± 
2.5 kg/m2, respectively. There were no significant differences in these parameters 
among the 3 study groups at baseline. In addition, the 3 study groups were similar 
with regard to initial serum concentrations of 25(OH)D, iPTH, and calcium (Tab. 10). 
At 4.08 (1.89-7.70) pmol/L at baseline, median serum iPTH was in the upper normal 
range, and 8 subjects (30.8%) already presented secondary hyperparathyroidism as 
a result of vitamin D deficiency. Furthermore, we found a statistically significant 
negative linear correlation between iPTH and serum 25(OH)D (r = -0.463, P = 
0.017). 
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Tab. 9: Baseline characteristics of subjects and dropouts (n = 26)1 
1 There were no significant differences between the groups at baseline. 2 Means ± SDs 
(all such values). 
 
Mushrooms’ vitamin D2 content 
Our study’s brown button mushrooms cultivated in the dark had very low concentra-
tions of vitamin D2 (0.18 µg/100 g fresh weight). The conversion of ergosterol to vi-
tamin D2 under UV-B irradiation in this study was very high, and we achieved con-
centrations of 491 µg/100g fresh weight (56.8 µg vitamin D2/g dry solids).  
Time course of the main serum parameters 
The time course data of serum 25(OH)D concentrations for each study group over 
the 5-week period are presented in Tab. 10 and Fig. 8. The primary objective was to 
test the efficacy of the vitamin D2-enhanced mushrooms to improve the 25(OH)D 
status. The data show that one week after the last consumption of such mushrooms 
at week 4, the mushroom group’s serum 25(OH)D was significantly higher than that 
in the placebo group (P <0.0001) (Tab. 10). 
A secondary objective consisted of testing the bioavailability of vitamin D2 from the 
UV-B treated mushrooms compared to a common vitamin D2 supplement. When 
modelling the development of 25(OH)D concentrations as a linear function of time 
(mixed regression model), we found that the mushroom and supplement groups in-
creased their 25(OH)D concentrations significantly over the study period by          
3.9 nmol/L per week (95% CI: 2.9, 4.8; P <0.0001) and by 4.7 nmol/L per week 
(95% CI: 3.8, 5.7; P <0.0001) (Fig. 1). Regression slopes of the concentrations of 
the serum 25(OH)D in the mushroom and supplement groups did not significantly 
Variables Mushroom       
group (n = 8) 
Supplement group 
(n = 9) 
Placebo group 
(n = 9) 
male:female (n) 3:5 4:5 2:7 
Age (y) 28.6 ± 4.32 31.1 ± 6.7 32.4 ± 6.0 
BMI (kg/m2) 22.0 ± 1.7 23.7 ± 2.1 20.6 ± 2.6 
study dropouts 1 at week 0 1 at week 5 - 
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differ from one another (P = 0.20). The mean increase in serum 25(OH)D in the first 
4 weeks per 100 IU of vitamin D2 was 0.5 nmol/L.  
 
Tab. 10: Laboratory values in the three study arms1 
 
 
1 Mean ± SD (all such values). iPTH, intact parathyroid hormone. 2 Values at each time of 
measurement with different superscript letters are significantly different from each other 
(one-factor ANOVA and post hoc analysis with Tukey’s test). 3 Reference range. 4-6 Sig-
nificantly different from the following mean in the same column (paired t test): 4P <0.05, 
5P <0.01, 6P <0.001. 
 
Further analysis showed that already two weeks after the first consumption of the 
vitamin D2-enhanced mushrooms, the two interventional groups’ serum 25(OH)D 
concentrations were significantly higher than in the placebo group (P = 0.001) (Tab. 
10). Furthermore, the data reveal significant within-subject changes in serum 
25(OH)D in all three study groups already at week 1. During the first week, serum 
25(OH)D rose significantly (P <0.001) by 33.1% and 46.1% in the mushroom and 
supplement groups, respectively. In addition, serum 25(OH)D decreased significantly 
Serum    pa-
rameter and 
time (week) 
Mushroom 
group 
(n = 8) 
Supplement 
group 
(n = 9) 
Placebo 
group              
(n = 9) 
P2 
25(OH)D (75-175 nmol/L)3 
0 34.0 ± 11.06 28.7 ± 10.06 38.7 ± 14.24 0.16 
1 45.2 ± 7.0 42.0 ± 9.24 35.0 ± 13.0 0.12 
2 47.2 ± 8.0a 46.2 ± 8.0a, 4 31.2 ± 9.7b, 4 0.001 
3 51.0 ± 11.2a 50.7 ± 7.7a 27.5 ± 7.7b, 4 <0.0001 
4 51.5 ± 7.7a, 5 48.2 ± 8.7a, 4 24.5 ± 7.2b, 4 <0.0001 
5 56.7 ± 7.2a 58.0 ± 11.2a 28.7 ± 8.7b <0.0001 
iPTH (1.2-4.5 pmol/L) 
0 3.36 ± 1.01 4.67 ± 1.56 4.28 ± 1.95 0.24 
4 3.20 ± 1.35 4.24 ± 1.21 3.78 ± 1.26 0.26 
Calcium (2.2-2.7 mmol/L) 
0 2.53 ± 0.08 2.47 ± 0.08 2.48 ± 0.096 0.33 
4 2.43 ± 0.07 2.40 ± 0.13 2.37 ± 0.09 0.44 
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(P = 0.03) by - 6.5% in the placebo group. The development of hypercalcaemia (se-
rum calcium >2.7 mmol/L) was the main safety criteria for the vitamin D2 admini-
stration. Serum calcium remained within the reference range at all time points. No 
physical symptoms were reported during the study.  Neither at baseline nor week 4 
did the serum concentrations in iPTH and calcium differ significantly among the three 
study groups (Tab. 10). The correlation between the 4-week changes in both inter-
vention groups from serum 25(OH)D and iPTH at baseline revealed a negative but 
non-significant association (r = -0.449, P = 0.071). 
 
 
Fig. 8: Time course of the mean changes in serum 25(OH)D over the 5-week study pe-
riod in subjects who consumed four times (weeks 0, 1, 2, 3) mushrooms enhanced with 
vitamin D2 via UV-B irradiation (mushroom group, n = 8, ●) or vitamin D2-containing 
supplements (supplement group, n  = 9, ∆)  or placebo (placebo group, n = 9, ■) at the 
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end of the winter. Error bars are 2 SE. At week 5 one subject dropped out of the supple-
ment group. Concentrations were significantly different (ANOVA, Tukey’s test) between 
the mushroom and placebo groups, and between the supplement and placebo groups 
from week 2 onward (wk 2: P = 0.002; P = 0.004, respectively; weeks 3, 4, 5:              
P <0.0001). Time courses for serum 25(OH)D over the study period in the mushroom 
and supplement groups did not differ significantly. 
 
2.5.4 Discussion 
Here we describe for the first time in humans that UV irradiation of mushrooms cre-
ates an excellent source of vitamin D2 which has equivalent bioavailability as a vita-
min D2 supplement.   
The rapid serum 25(OH)D increase in our mushroom group is a clear demonstration 
that ingesting 28 000 IU vitamin D2 once a week for 4 weeks via UV-B-irradiated and 
vitamin D2-enhanced mushrooms is effective in improving vitamin D status in young, 
healthy adults. Already one week after their first ingestion of UV-B-irradiated mush-
rooms, serum 25(OH)D rose significantly. Furthermore, it was significantly higher 
than in placebo group one week after the second administration of enhanced mush-
rooms (week 2).  
Most studies on the bioavailability of vitamin D in humans have been conducted us-
ing supplements, not natural food sources. Consistent with our observation of 
equivalent vitamin D2 bioavailability from a soup prepared with UV-irradiated mush-
rooms and supplement, an earlier study [161] demonstrated the same efficiency 
with non-irradiated, but lyophilized and homogenized mushrooms in humans. Both 
findings disprove the hypothesis of Van-den-Berg (1997), who maintained that the 
bioavailability of vitamin D from natural food sources is probably lower than from 
supplements.  
By our weekly vitamin D2 supplementation of 28 000 IU (daily equivalent of 
4000 IU), we found after one month a mean increase in serum 25(OH)D of 
0.5 nmol/L for every 100 IU of vitamin D ingested. Evaluating our dose-response 
effect with the reported increase by approximately 1–2 nmol/L in 25(OH)D for each 
additional 100 IU of vitamin D3 [162] is not appropriate, because a plateau in serum 
25(OH)D was not achievable over such a short period. Therefore, we examined sup-
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plementation studies using comparable doses of vitamin D2 and time periods. 
Mastaglia et al. reported a dose-response in the first month of 0.43 nmol/L for every 
100 IU vitamin D2 by supplementing weekly 35 000 IU of vitamin D2, resembling our 
results although they used a 25% higher dose [163]. At their study’s conclusion (3 
months), dose-response rose to 0.71 nmol/L. Considering the differences in doses 
and time, our results also concur with dose-responses reported by others [164,148]. 
One of our study’s limitations is that the accuracy of the RIA method used to deter-
mine 25(OH)D2 was found to be lower than indicated by the manufacturer 
[165,166], so it is possible that total serum 25(OH)D was underestimated. 
Other authors showed that a single dose of 50 000 IU of vitamin D2 or vitamin D3 
produced similar increases in serum 25(OH)D over the first 3 days, but serum 
25(OH)D began to fall immediately thereafter in the vitamin D2 group until, by     
day 14, it reached baseline concentrations [167]. In contrast, serum 25(OH)D con-
centrations continued to rise until day 14 in the vitamin D3 group, then falling slowly 
over the following 14 days. 
We did not compare the potencies of these two types of vitamin D, but we could not 
confirm the reported short initial increase followed by a rapid fall in serum 25(OH)D 
after vitamin D2 supplementation [167]. When adjusted for a concomitant increase in 
serum 25(OH)D in the placebo group in the last week (due to the confounding effect 
of cutaneous vitamin D3 synthesis), the high serum 25(OH)D concentrations in both 
interventional groups achieved remained constant during the follow-up period.  
Secondary hyperparathyroidism at baseline as a major clinical sign of vitamin D defi-
ciency was present in almost a third of our subjects with low 25(OH)D status, espe-
cially in those with very low serum 25(OH)D concentrations (≤25 nmol/L). In addi-
tion, we observed a negative correlation (r = -0.449, P = 0.071) between serum 
25(OH)D increase due to the weekly intake of 28 000 IU vitamin D2 and the change 
in serum iPTH. 
As anticipated, and in light of  the current state of knowledge [168,169], the vitamin 
D2 dose of an average of 4 000 IU/d used in this study was safe, and we observed no 
cases of hypercalcaemia or any adverse events. 
Our results demonstrate for the first time that the bioavailability of vitamin D2 from 
vitamin D2-enhanced button mushrooms via UV-B irradiation was effective in improv-
ing vitamin D status in young, healthy adults. Furthermore, we did not observe any 
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differences in the absorption rate and metabolism of vitamin D2 from UV-B-irradiated 
mushrooms and a vitamin D2 supplement in raising circulating serum 25(OH)D con-
centrations.  
In conclusion, as the vitamin D2 enhancement of mushrooms boosts their nutraceuti-
cal value, it would provide a worthwhile means of improving the vitamin D mainte-
nance in the general population. Further research and development are required to 
find solutions for making such vitamin D2-enhanced mushrooms commercially avail-
able in a safe and affordable manner.  
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3 Summary 
 
The first two studies investigated the course of the nutritional status in patients un-
dergoing allogeneic haematopoietic cell transplantation (alloHCT) and the validity of 
nutritional markers as independent risk factors for outcome. In line with others, we 
detected an overall good nutritional status before alloHCT by employing quick 
screening tools such as BMI and the SGA questionnaire for identifying malnutrition. 
However, upon closer inspection, we observed unintentional weight loss previous to 
alloHCT to be a frequent condition, detecting many more underweight patients using 
age- and gender-specific BMI classification and overall low bioelectrical impedance 
phase angle values at admission. Deterioration in nutritional status during the early 
post-transplant period was significant in the cohort. Furthermore, we identified ano-
rexic patients and those with clinically-relevant aGVHD (≥°II) to have an increased 
risk for a decline in nutritional status during early rehabilitation. In addition, it could 
be demonstrated for the first time that the pretransplant phase angle (≤25th percen-
tile) used as a standardised value was an independent predictor for 2-year overall 
survival, non-relapse mortality and progression-free survival. BMI adjusted for age 
and gender emerged as an independent risk factor for OS and NRM. Both of these 
nutritional markers performed better than numerous generally-accepted risk factors, 
and they were the only significant prognostic values for outcome in this cohort be-
sides HLA-C compatibility, donor and remission status. In addition, these two nutri-
tional markers are theoretically modifiable during the often lengthy treatment period 
before transplantation. Further investigation is necessary to demonstrate whether or 
not the phase angle can be increased by strategies that enhance muscle mass via 
physical training together with nutritional support, and whether it can prevent dete-
rioration in nutritional status and lead to beneficial effects on outcome after alloHCT. 
The third study investigated the association between AOX status (α-tocopherol, 
ascorbic acid and ß-carotene) in buccal mucosa cells (BMC) or plasma and the risk of 
developing oral mucositis (OM) after conditioning chemotherapy. We observed no 
significant differences in baseline AOX concentrations in plasma or BMC among the 
different OM groups (no or mild, ulcerative and severe OM), revealing that no single 
AOX has predictive value for the incidence or severity of OM after conditioning che-
motherapy. However, patients with an overall good plasma AOX status tended to re-
quire a shorter duration of parenteral nutrition, which is a relevant clinical and eco-
nomic marker for OM treatment compared to patients with at least one plasma AOX 
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beneath the normal range. These findings may indicate that an intact antioxidative 
network is more relevant than any one AOX for lowering the OM risk. Future studies 
should consider both the exogenous- and endogenous AOX systems. 
The fourth study revealed a generally low serum 25-hydroxyvitamin D [25(OH)D3] 
status in these patients at admission. Furthermore, their 25(OH)D3 status remained 
low during the early post-transplant period, showing a trend towards further deterio-
ration, especially in patients with corticosteroid-treated aGVHD. In addition, we con-
ducted a detailed investigation of the impact of well-known influencing factors on 
baseline serum 25(OH)D3 status, revealing only higher body fat mass to be an inde-
pendent risk factor for reduced baseline status. In fact the most important influenc-
ing factors, namely dietary factors and season, revealed no detectable impact, most 
probably due to inadequate oral intake, prolonged disease history, and hospitalisa-
tion. In conclusion, these results provide a clear rationale for the use at least of 
vitamin D-containing multivitamin preparations in standard multivitamin prescrip-
tions, and for the monitoring of vitamin D status at regular intervals from the date of 
diagnosis. 
The fifth study was a randomised controlled trial revealing for the first time in 
humans that the bioavailability of vitamin D2 from vitamin D2-enhanced button 
mushrooms via UV-B irradiation is effective in improving vitamin D status in young, 
healthy adults and not different than a vitamin D2 supplement. The vitamin D2 
enhancement of mushrooms boosts their nutraceutical value by creating both an 
abundant and excellent source of vitamin D2 that opens up new opportunities in 
fighting widespread vitamin D deficiency. 
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4 Zusammenfassung 
Die ersten zwei Studien untersuchten den Verlauf des Ernährungsstatus bei Patien-
ten, die eine allogene hämatopoetische Zelltransplantation (alloHZT) erhielten, sowie 
die Validität von Ernährungsparametern als unabhängige Risikofaktoren für das Out-
come. In Übereinstimmung mit anderen Studien stellten wir vor Beginn der alloHZT 
mithilfe einfacher Screening-Verfahren für Mangelernährung wie BMI und SGA-
Fragenbogen einen insgesamt guten Ernährungsstatus fest. Jedoch bei näherer Be-
trachtung zeigte sich häufig ein unbeabsichtigter Gewichtsverlust vor Beginn der 
alloHZT. Des Weiteren wurden bei Aufnahme deutlich mehr untergewichtige Patien-
ten durch den Einsatz von alters- und geschlechtsspezifischer BMI-Klassifikation er-
mittelt und allgemein niedrige Phasenwinkel-Werte mittels bioelektrischer Impedanz-
analyse gemessen. Signifikante Verschlechterungen des Ernährungsstatus in der 
frühen Phase nach Transplantation waren in dieser Kohorte häufig. Darüber hinaus 
identifizierten wir anorektische Patienten und solche mit einer klinisch relevanten 
aGVHD (≥°II) als solche mit erhöhtem Risiko für eine Verschlechterung des Ernäh-
rungsstatus während der frühen Rehabilitationsperiode. Diese Ergebnisse zeigen 
erstmals, dass der Phasenwinkel vor Transplantation (≤25te Perzentile) als standar-
disierter Wert, ein unabhängiger Prädiktor für das 2-Jahres Gesamtüberleben, thera-
piebedingte Mortalität (NRM) und progressionsfreies Überleben (PFS) ist. Des Weite-
ren stellte sich der alters- und geschlechtsadaptierte BMI als ein unabhängiger 
Risikofaktor für Gesamtüberleben und therapiebedingte Mortalität heraus. Beide 
Ernährungsparameter übertrafen zahlreiche allgemein anerkannte Risikofaktoren in 
ihrer Aussagekraft und waren neben HLA-C-Kompatibilität, Donor- und Remissions-
status die einzigen signifikanten prognostischen Werte für das Outcome in der vorlie-
genden Kohorte. Zusätzlich lassen sich diese Ernährungsparameter während der häu-
fig langen Behandlungsperiode vor Transplantation theoretisch beeinflussen. Weitere 
Untersuchungen sind nötig um zu zeigen, ob der Phasenwinkel mittels Strategien 
erhöht werden könnte, welche beispielsweise die Muskelmasse durch körperliches 
Training in Kombination mit Ernährungstherapie steigern, und ob auf diese Weise 
eine Verschlechterung des Ernährungsstatus verhindert würde und zu positiven    
Effekten für das Outcome nach alloHZT führen würde.  
In der dritten Studie wurde der Zusammenhang untersucht zwischen dem AOX-
Status (α-Tocopherol, Ascorbinsäure und ß-Carotin) in den bukkalen Mukosazellen 
(BMZ) sowie dem Plasma und dem Risiko eine orale Mukositis (OM) nach der Konditi-
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onierungschemotherapie zu entwickeln. Es konnten jedoch keine signifikanten Unter-
schiede in den AOX-Ausgangswerten im Plasma oder in den BMZ zwischen den ver-
schiedenen OM-Gruppen (keine oder leichte, ulzerierende und schwere OM) festge-
stellt werden. Dies zeigte, dass kein einzelner AOX-Wert einen prädikativen Wert für 
die Inzidenz oder die Schwere der OM nach Konditionierungschemotherapie hat. Hin-
gegen benötigten Patienten mit einem insgesamt guten AOX-Status im Vergleich zu 
Patienten mit mindestens einem AOX-Wert unterhalb des Normbereiches tendenziell 
weniger Tage parenterale Ernährung, was ein relevanter klinischer und ökonomischer 
Parameter für die Behandlung von OM ist. Diese Ergebnisse können darauf hinwei-
sen, dass für die Reduktion des OM-Risikos ein intaktes antioxidatives Netzwerk 
wichtiger ist, als ein einzelner AOX. Weiterführende Studien sollten sowohl die exo-
genen wie auch die endogenen AOX-Systeme berücksichtigen. 
Die vierte Studie zeigte bei diesen Patienten einen insgesamt niedrigen 25-Hydroxy-
vitamin-D [25(OH)D3] Status im Serum zum Zeitpunkt der Aufnahme. Darüber 
hinaus blieb der Vitamin D Status in der frühen Posttransplantationsphase erniedrigt 
und zeigte eine Tendenz zu einer weiteren Verschlechterung, besonders bei Patienten 
mit Kortikosteroid-behandelter aGVHD. Außerdem führten wir eine detaillierte Unter-
suchung bekannter Einflussfaktoren auf den 25(OH)D3 Basiswert durch, bei der sich 
lediglich eine erhöhte Körperfettmasse bei Aufnahme als unabhängiger Risikofaktor 
für einen reduzierten Ausgangswert herausstellte. Die wichtigsten Einflussfaktoren, 
nämlich Ernährungsfaktoren sowie Jahreszeit, hatten hingegen keinen feststellbaren 
Einfluss, wahrscheinlich aufgrund unzureichender oraler Aufnahme, prolongiertem 
Krankheitsverlauf und häufigem stationären Aufenthalt. In der Zusammenschau lie-
fern diese Ergebnisse ein klares Argument für den Einsatz von mindestens Vitamin 
D-haltigen Multivitaminpräparaten und für die Überwachung des Vitamin D Status in 
regelmäßigen Abständen ab dem Zeitpunkt der Diagnose. 
Die fünfte Studie war eine randomisierte Kontrollstudie, die erstmals am Menschen 
zeigen konnte, dass Vitamin D2 aus UVB-behandelten und dadurch Vitamin D2-
optimierten Champignons den Vitamin D Status junger, gesunder Erwachsener signi-
fikant verbessern konnte. Weiterhin war die Bioverfügbarkeit vergleichbar mit einem 
herkömmlichen Vitamin D2 Präparat. Die Vitamin D2 Optimierung von Champignons 
ist eine reichhaltige und hervorragende Quelle für Vitamin D2 und eröffnet neue Mög-
lichkeiten, die weitverbreitete Vitamin D Unterversorgung zu bekämpfen.  
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